

washed with solvent (20 ml) having the same composition as the mixed solvent used in the reaction. The filtrate and the washings were combined, followed by concentration under reduced pressure to give ethyl 3-((4*R*)-amino-(3*R*)-hydroxypiperidin-1-yl)benzoate (11 mg, 100%).

DMSO (3.0 ml) was added to ethyl 3-((4*R*)-amino-(3*R*)-hydroxypiperidin-1-yl)benzoate (87 mg, 0.33 mmol) to prepare a solution. 2-Bromopyrimidine (55 mg, 0.33 mmol) and *N,N*-diisopropylethylamine (320  $\mu$ l, 1.9 mmol) were successively added to the solution, and a reaction was allowed to proceed at 120 °C for 14 h. The reaction mixture was returned to room temperature, and water (500 ml) was added thereto, followed by extraction three times with ethyl acetate (250 ml). The combined organic layers were washed twice with water (200 ml) and twice with saturated brine (200 ml), were then dried over anhydrous MgSO<sub>4</sub>, and were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (benzene/ethyl acetate, 1:4) to prepare compound **57** (51 mg, 45%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.39 (3H, t, Et), 1.80 (1H, dddd, piperidine), 2.14 (1H, dddd, piperidine), 2.74 (1H, dd, piperidine), 2.89 (1H, ddd, piperidine), 3.72–3.86 (3H, m, piperidine), 3.97 (1H, ddd, piperidine), 4.37 (2H, q, Et), 6.64 (1H, t, pyrimidine), 7.14 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.32 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.53 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.63 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 8.29 (2H, d, pyrimidine); TSPMS *m/z* 343 (M+H)<sup>+</sup>.

**6.7.2.8. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[3-((3*R*)-hydroxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl)benzoylamino]propionate.** 3-((3*R*)-Hydroxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl)benzoic acid was prepared from compound **57** by the same procedure as employed for compound **26** from compound **29**.

The title compound was prepared from 3-((3*R*)-hydroxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl)benzoic acid by the same procedure as employed for compound **30**. Yield: (18 mg, 21%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.29 (9H, s, *t*-Bu), 1.72–1.83 (1H, m, piperidine), 2.09–2.15 (1H, m, piperidine), 2.75 (1H, dd, piperidine), 2.90 (1H, ddd, piperidine), 3.54–3.63 (1H, m, piperidine), 3.70–3.83 (3H, m, piperidine and CONHCH<sub>2</sub>CH), 3.86–3.95 (2H, m, piperidine and CONHCH<sub>2</sub>), 3.98 (1H, ddd, piperidine), 6.62 (1H, t, pyrimidine), 7.10 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.18 (1H, br d, C<sub>6</sub>H<sub>4</sub>), 7.31 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.43 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.47–7.60 (3H, m, C<sub>6</sub>H<sub>5</sub>), 7.84–7.88 (2H, m, C<sub>6</sub>H<sub>5</sub>), 8.29 (2H, d, pyrimidine); TSPMS *m/z* 597 (M+H)<sup>+</sup>;  $[\alpha]_D^{25}$  +75 (*c* 0.48, CH<sub>2</sub>Cl<sub>2</sub>).

**6.7.2.9. Compound 32.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[3-((3*R*)-hydroxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl)benzoylamino]propionate by the same procedure as employed for compound **22**. Yield: (3.1 mg, 21%); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$ : 1.68 (1H, dddd, piperidine), 1.95 (2H, dddd, tetrahydropyrimidine), 1.92–2.02 (1H, m, piperidine), 2.67 (1H, dd, piperidine), 2.83 (1H, ddd, piperidine), 3.26–3.32 (1H, m, piperidine), 3.36

(4H, br t, tetrahydropyrimidine), 3.50–3.57 (1H, m, piperidine), 3.56 (1H, dd, CONHCH<sub>2</sub>), 3.67 (1H, dd, CONHCH<sub>2</sub>), 3.74 (1H, dd, CONHCH<sub>2</sub>CH), 3.77–3.85 (1H, m, piperidine), 3.91 (1H, m, piperidine), 7.11 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.24 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.31 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.42 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.46–7.52 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.52–7.58 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.85–7.89 (2H, m, C<sub>6</sub>H<sub>5</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>32</sub>N<sub>6</sub>O<sub>6</sub>S: 545.2182. Found: 545.2189;  $[\alpha]_D^{25}$  +70 (*c* 0.14, MeOH).

### 6.7.3. Preparation of compound 33

**6.7.3.1. Compound 55.** THF (5.0 ml) was added to sodium hydride (60%, 35 mg, 0.87 mmol) in an argon atmosphere to prepare a suspension. Separately, compound **53** (208 mg, 0.72 mmol) was dissolved in THF (2.0 ml). This solution was added dropwise to the above suspension at room temperature, and the mixture was stirred for 30 min. A solution (1.0 ml) of methyl iodide (67  $\mu$ l, 1.1 mmol) in THF was added dropwise thereto. The mixture was stirred for 4 h, an aqueous ammonium chloride solution was then added to stop the reaction, and water (100 ml) was added thereto. The mixture was extracted twice with ethyl acetate (100 ml). The combined organic layers were then dried over anhydrous MgSO<sub>4</sub> and were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1) to prepare the title compound (77 mg, 35%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.39 (3H, t, Et), 1.70 (1H, m, piperidine), 2.06 (1H, m, piperidine), 2.68 (1H, dd, piperidine), 2.84 (1H, ddd, piperidine), 3.34 (1H, ddd, piperidine), 3.44 (1H, ddd, piperidine), 3.55 (3H, s, OMe), 3.63 (1H, br d, piperidine), 3.88 (1H, ddd, piperidine), 4.37 (2H, q, Et), 7.12 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.32 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.55 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.60 (1H, br s, C<sub>6</sub>H<sub>4</sub>); TSPMS *m/z* 305 (M+H)<sup>+</sup>.

**6.7.3.2. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[3-((3*R*)-methoxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl)benzoylamino]propionate.** 1,4-Dioxane (4.0 ml) and water (2.0 ml) were successively added to compound **55** (69 mg, 0.23 mmol) to prepare a solution. 10% Pd/C (18 mg) was added to the solution, and the mixture was stirred in a hydrogen atmosphere at room temperature for 4 h. The insolubles were filtered and were washed with a solvent (90 ml) having the same composition as the mixed solvent used in the reaction. The filtrate and the washings were combined followed by concentration under reduced pressure to give ethyl 3-((4*R*)-amino-(3*R*)-methoxypiperidin-1-yl)benzoate (66 mg, 100%).

DMSO (2.5 ml) was added to the ethyl 3-((4*R*)-amino-(3*R*)-methoxypiperidin-1-yl)benzoate (66 mg, 0.23 mmol) thus obtained to prepare a solution. *N,N*-Diisopropylethylamine (230  $\mu$ l, 1.3 mmol) and 2-bromopyrimidine (42 mg, 0.27 mmol) were added in that order to the solution. A reaction was allowed to proceed at 120 °C for 24 h, and the temperature of the reaction mixture was then returned to room temperature. Water (500 ml) was added thereto, and the mixture was extracted twice with ethyl acetate (500 ml). The combined organic layers were washed twice with water (500 ml) and once with saturated brine (500 ml), were

dried over anhydrous  $\text{MgSO}_4$ , and were then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate) to give ethyl 3-[(3*R*)-methoxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoate (**58**) (34 mg, 40%).

THF (1.5 ml) and MeOH (0.50 ml) were added to compound **58** (34 mg, 0.096 mmol) thus obtained to prepare a solution, and a 1 N NaOH (0.50 ml) was added to the solution. A reaction was allowed to proceed at 50 °C for 3 h. The temperature of the reaction mixture was then returned to room temperature, the reaction mixture was adjusted to pH 3 by the addition of 1 N hydrochloric acid, and water (50 ml) was added thereto. The mixture was extracted twice with ethyl acetate (50 ml), and the extract was then dried over anhydrous  $\text{MgSO}_4$  and was concentrated under reduced pressure to give 3-[(3*R*)-methoxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoic acid (29 mg, 95%).

DMF (1.5 ml) was added to 3-[(3*R*)-methoxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoic acid (28 mg, 0.086 mmol) to prepare a solution, and *tert*-butyl (2*S*)-*N*-benzenesulfonyl-2,3-diaminopropionate (32 mg, 0.10 mmol) was added to the solution. Further, 1-hydroxybenzotriazole (19 mg, 0.14 mmol), *N*-methylmorpholine (47  $\mu\text{l}$ , 0.43 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (34 mg, 0.18 mmol) were added thereto, and a reaction was allowed to proceed at room temperature for 2.5 h. An aqueous  $\text{NaHCO}_3$  solution (10 ml) was added to stop the reaction, and water (100 ml) was added thereto. The mixture was extracted twice with ethyl acetate (100 ml), and the combined organic layers were washed with saturated brine (100 ml) and were dried over anhydrous  $\text{MgSO}_4$ , followed by concentration under reduced pressure. The residue was purified by column chromatography on silica gel ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$ , 10:1) to prepare the title compound (36 mg, 26% (four steps));  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$ : 1.29 (9H, s, *t*-Bu), 1.65–1.70 (1H, m, piperidine), 2.41 (1H, m, piperidine), 2.85 (1H, dd, piperidine), 3.01 (1H, ddd, piperidine), 3.37 (1H, ddd, piperidine), 3.49 (3H, s, OMe), 3.49–3.58 (1H, m,  $\text{CONHCH}_2$ ), 3.60–3.68 (1H, m, piperidine), 3.87–4.03 (4H, m, piperidine and  $\text{CONHCH}_2\text{CH}$ ), 6.65 (1H, t, pyrimidine), 7.09 (1H, d,  $\text{C}_6\text{H}_4$ ), 7.21 (1H, d,  $\text{C}_6\text{H}_4$ ), 7.32 (1H, dd,  $\text{C}_6\text{H}_4$ ), 7.46 (1H, br s,  $\text{C}_6\text{H}_4$ ), 7.48–7.61 (3H, m,  $\text{C}_6\text{H}_5$ ), 7.84–7.88 (2H, m,  $\text{C}_6\text{H}_5$ ), 8.29 (2H, d, pyrimidine); TSPMS  $m/z$  611 ( $\text{M}+\text{H}$ ) $^+$ ;  $[\alpha]_{\text{D}}^{25}$  +17 (c 0.54,  $\text{CH}_2\text{Cl}_2$ ).

**6.7.3.3. Compound 33.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[(3*R*)-methoxy-(4*R*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoylamino]propionate by the same procedure as employed for compound **22**. Yield: (15 mg, 32% (two steps));  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 1.71 (1H, dddd, piperidine), 1.95 (2H, dddd, tetrahydropyrimidine), 1.95–2.03 (1H, m, piperidine), 2.59 (1H, dd, piperidine), 2.82 (1H, ddd, piperidine), 3.22 (1H, ddd, piperidine), 3.27–3.38 (1H, m,  $\text{CONHCH}_2$ ), 3.36 (4H, br t, tetrahydropyrimidine), 3.50 (3H, s, OMe), 3.45–3.60 (1H, m, piperidine), 3.67–3.82 (3H, m, piperidine)

and  $\text{CONHCH}_2\text{CH}$ ), 4.17 (1H, ddd, piperidine), 7.15 (1H, ddd,  $\text{C}_6\text{H}_4$ ), 7.27 (1H, d,  $\text{C}_6\text{H}_4$ ), 7.32 (1H, dd,  $\text{C}_6\text{H}_4$ ), 7.46–7.52 (3H, m,  $\text{C}_6\text{H}_4$  and  $\text{C}_6\text{H}_5$ ), 7.53–7.59 (1H, m,  $\text{C}_6\text{H}_5$ ), 7.84–7.89 (2H, m,  $\text{C}_6\text{H}_5$ ); FAB-HRMS ( $\text{M}+\text{H}$ ) $^+$  calcd for  $\text{C}_{26}\text{H}_{34}\text{N}_6\text{O}_6\text{S}$ : 559.2339. Found: 559.2350;  $[\alpha]_{\text{D}}^{25}$  +93 (c 0.44, MeOH).

#### 6.7.4. Preparation of compound 34 (method A)

**6.7.4.1. (3*S*)-Aminopiperidin-2-one.** MeOH (770 ml) was added to L-ornithine hydrochloride (131 g, 0.78 mol) in an argon atmosphere to prepare a suspension, to which thionyl chloride (170 ml, 2.0 mol) was added dropwise at an internal temperature of  $-45$  °C over a period of 30 min or longer, followed by stirring for 30 min. The temperature of the reaction mixture was then returned to room temperature, and the reaction mixture was vigorously stirred for 19 h and was concentrated under reduced pressure. Water (500 ml) was then added to the residue to prepare a solution. The solution was subjected to column chromatography using a column packed with an Amberlite IRA-400 ( $\text{OH}^-$ ) anion exchange resin (1.1 kg), eluting with water to prepare the title compound as a crude product. MeOH (500 ml) was added to the crude product to prepare a solution, and the solution was slowly poured into  $\text{CHCl}_3$  (5.0 l). The suspension thus obtained was then filtered, and the filtrate was concentrated under reduced pressure to prepare the title compound (81 g, 69%);  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 1.48 (1H, m, piperidine), 1.72 (2H, m, piperidine), 1.99 (1H, dddd, piperidine), 3.16 (2H, dd, piperidine), 3.24 (1H, dd, piperidine); EIMS  $m/z$  114 ( $\text{M}$ ) $^+$ .

**6.7.4.2. (3*S*)-Aminopiperidine.** THF (100 ml) was added to aluminum lithium hydride (3.3 g, 87 mmol) to prepare a suspension, to which (3*S*)-aminopiperidin-2-one (4.1 g, 27 mmol) was added under ice cooling. The temperature of the reaction mixture was returned to room temperature, and the reaction mixture was then stirred for 5.5 h, and, while vigorously stirring, water (3.3 ml), 5 N NaOH (3.3 ml), and water (10 ml) were added in that order to stop the reaction, followed by filtration. The filtrate was then dried over anhydrous  $\text{MgSO}_4$ . A 4 N hydrogen chloride ethyl acetate solution (14 ml) was added thereto, and the mixture was concentrated under reduced pressure. The residue was subjected to azeotropic distillation with MeOH to prepare dihydrochloride of the title compound (5.1 g, 100%);  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 1.75 (1H, dddd, piperidine), 1.90 (1H, m, piperidine), 2.09 (1H, dddd, piperidine), 2.23 (1H, br d, piperidine), 3.02 (1H, ddd, piperidine), 3.09 (1H, dd, piperidine), 3.41 (1H, br d, piperidine), 3.62 (2H, m, piperidine); EIMS  $m/z$  100 ( $\text{M}$ ) $^+$ .

**6.7.4.3. 3-[(3*S*)-Aminopiperidin-1-yl]benzotrile.** The title compound was prepared from (3*S*)-aminopiperidine by the same procedure as employed for compound **23**. Yield: (137 mg, 30%);  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 1.32 (1H, ddd, piperidine), 1.50–1.67 (1H, m, piperidine), 1.79–1.87 (1H, m, piperidine), 1.96 (1H, dddd, piperidine), 2.62 (1H, dd, piperidine), 2.82 (1H, ddd, piperidine), 2.88 (1H, dddd, piperidine), 3.53 (1H, ddd, piperidine), 3.65 (1H, dddd, piperidine), 7.05 (1H, ddd,

C<sub>6</sub>H<sub>4</sub>), 7.20–7.25 (2H, m, C<sub>6</sub>H<sub>4</sub>), 7.33 (1H, ddd, C<sub>6</sub>H<sub>4</sub>); EIMS *m/z* 201 (M)<sup>+</sup>.

**6.7.4.4. 3-[(3*S*)-(Pyrimidin-2-ylamino)piperidin-1-yl]benzotrile.** The title compound was prepared from 3-[(3*S*)-aminopiperidin-1-yl]benzotrile by the same procedure as employed for compound **25**. Yield: (144 mg, 75%); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.60–1.81 (2H, m, piperidine), 1.83–1.93 (1H, m, piperidine), 1.96–2.04 (1H, m, piperidine), 2.95 (1H, dd, piperidine), 3.11 (1H, dd, piperidine), 3.41 (1H, ddd, piperidine), 3.75 (1H, dd, piperidine), 4.15 (1H, dddd, piperidine), 6.58 (1H, t, pyrimidine), 7.06 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.15 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.24 (1H, br s, C<sub>6</sub>H<sub>4</sub>), 7.29 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 8.32 (2H, d, pyrimidine); EIMS *m/z* 279 (M)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +8.6 (c 0.67, CH<sub>2</sub>Cl<sub>2</sub>).

**6.7.4.5. 3-[(3*S*)-(Pyrimidin-2-ylamino)piperidin-1-yl]benzoic acid.** The title compound was prepared from 3-[(3*S*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzotrile by the same procedure as employed for compound **26** from compound **25**. Yield: (79 mg, 60%); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 1.46–1.67 (2H, m, piperidine), 1.74–1.84 (1H, m, piperidine), 1.91–1.99 (1H, m, piperidine), 2.64 (1H, dd, piperidine), 2.77 (1H, br dd, piperidine), 3.67 (1H, br d, piperidine), 3.83 (1H, br d, piperidine), 3.86–3.97 (1H, m, piperidine), 6.58 (1H, t, pyrimidine), 7.13 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.19 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.30 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.53 (1H, br s, C<sub>6</sub>H<sub>4</sub>), 8.29 (2H, d, pyrimidine); EIMS *m/z* 298 (M)<sup>+</sup>.

**6.7.4.6. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[3-[(3*S*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoylamino]propionate.** The title compound was prepared from 3-[(3*S*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoic acid by the same procedure as employed for compound **30**. Yield: (130 mg, 85%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.29 (9H, s, *t*-Bu), 1.62–1.71 (1H, m, piperidine), 1.71–1.81 (1H, m, piperidine), 1.85–2.00 (2H, m, piperidine), 3.02 (1H, dd, piperidine), 3.10–3.20 (1H, m, piperidine), 3.32–3.39 (1H, m, piperidine), 3.60 (1H, ddd, CONHCH<sub>2</sub>), 3.67 (1H, dd, piperidine), 3.85–3.96 (2H, m, CONHCH<sub>2</sub>CH), 4.16–4.25 (1H, m, piperidine), 6.53 (1H, t, pyrimidine), 7.10 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.16 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.29 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.44 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.46–7.52 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.54–7.59 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.83–7.87 (2H, m, C<sub>6</sub>H<sub>5</sub>), 8.29 (2H, d, pyrimidine); TSPMS *m/z* 581 (M+H)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +40 (c 0.54, CH<sub>2</sub>Cl<sub>2</sub>).

**6.7.4.7. Compound 34.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[3-[(3*S*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoylamino]propionate by the same procedure as employed for compound **22**. Yield: (59 mg, 59%); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.60 (1H, ddd, piperidine), 1.70–1.81 (1H, m, piperidine), 1.85–1.93 (4H, m, piperidine and tetrahydropyrimidine), 3.06 (1H, dd, piperidine), 3.10–3.15 (1H, m, piperidine), 3.28 (1H, m, piperidine), 3.33 (4H, br t, tetrahydropyrimidine), 3.48 (1H, dd, piperidine), 3.52 (1H, dd, CONHCH<sub>2</sub>), 3.65–3.72 (1H, m, piperidine), 3.71 (1H, dd, CONHCH<sub>2</sub>), 3.77 (1H, dd, CONHCH<sub>2</sub>CH), 7.13 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.26 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.31 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.46 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.47–7.53 (2H, m,

C<sub>6</sub>H<sub>5</sub>), 7.53–7.59 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.85–7.90 (2H, m, C<sub>6</sub>H<sub>5</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>32</sub>N<sub>6</sub>O<sub>5</sub>S: 529.2233. Found: 529.2239; [α]<sub>D</sub><sup>25</sup> +66 (c 0.57, MeOH).

### 6.7.5. Preparation of compound **35** (method A)

**6.7.5.1. (3*R*)-Aminopiperidin-2-one.** The title compound was prepared from *D*-ornithine hydrochloride by the same procedure as employed for (3*S*)-aminopiperidin-2-one. Yield: (1.7 g, 63%); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.48 (1H, m, piperidine), 1.72 (2H, m, piperidine), 1.99 (1H, dddd, piperidine), 3.16 (2H, dd, piperidine), 3.24 (1H, dd, piperidine); EIMS *m/z* 114 (M)<sup>+</sup>.

**6.7.5.2. (3*R*)-Aminopiperidine.** The title compound was prepared from (3*R*)-aminopiperidin-2-one by the same procedure as employed for (3*S*)-aminopiperidine. Yield: (1.0 g, 60%); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.75 (1H, dddd, piperidine), 1.90 (1H, m, piperidine), 2.09 (1H, dddd, piperidine), 2.23 (1H, br d, piperidine), 3.02 (1H, ddd, piperidine), 3.09 (1H, dd, piperidine), 3.41 (1H, br d, piperidine), 3.62 (2H, m, piperidine); EIMS *m/z* 100 (M)<sup>+</sup>.

**6.7.5.3. 3-[(3*R*)-(Pyrimidin-2-ylamino)piperidin-1-yl]benzotrile.** The title compound was prepared from (3*R*)-aminopiperidine by the same procedure as employed for compound **25**. Yield: (59 mg, 10% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.60–1.95 (3H, m, piperidine), 1.96–2.05 (1H, m, piperidine), 2.97 (1H, dd, piperidine), 3.11 (1H, ddd, piperidine), 3.37–3.45 (1H, m, piperidine), 3.74 (1H, dd, piperidine), 4.12–4.21 (1H, m, piperidine), 6.60 (1H, t, pyrimidine), 7.06 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.15 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.24 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.29 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 8.33 (2H, d, pyrimidine); TSPMS *m/z* 280 (M+H)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> –7.0 (c 0.65, CH<sub>2</sub>Cl<sub>2</sub>).

**6.7.5.4. 3-[(3*R*)-(Pyrimidin-2-ylamino)piperidin-1-yl]benzoic acid.** The title compound was prepared from 3-[(3*R*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzotrile by the same procedure as employed for compound **26** from compound **25**. Yield: (44 mg, 71%); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 1.45–1.66 (2H, m, piperidine), 1.74–1.82 (1H, m, piperidine), 1.95 (1H, br d, piperidine), 2.63 (1H, dd, piperidine), 2.76 (1H, ddd, piperidine), 3.65 (1H, br d, piperidine), 3.81 (1H, br d, piperidine), 3.86–3.96 (1H, m, piperidine), 6.57 (1H, t, pyrimidine), 7.11 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.18 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.28 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.52 (1H, br s, C<sub>6</sub>H<sub>4</sub>), 8.29 (2H, d, pyrimidine); TSPMS *m/z* 299 (M+H)<sup>+</sup>.

**6.7.5.5. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[3-[(3*R*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoylamino]propionate.** The title compound was prepared from 3-[(3*R*)-(pyrimidin-2-ylamino)piperidin-1-yl]benzoic acid by the same procedure as employed for compound **30**. Yield: (80 mg, 100%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.29 (9H, s, *t*-Bu), 1.63–1.72 (1H, m, piperidine), 1.73–1.82 (1H, m, piperidine), 1.86–2.00 (2H, m, piperidine), 3.03 (1H, dd, piperidine), 3.16 (1H, ddd, piperidine), 3.30–3.39 (1H, m, piperidine), 3.61 (1H, ddd, CONHCH<sub>2</sub>), 3.67 (1H, dd, piperidine), 3.88 (1H, m,

CONHCH<sub>2</sub>), 3.90–3.96 (1H, m, CONHCH<sub>2</sub>CH), 4.10–4.25 (1H, m, piperidine), 6.53 (1H, t, pyrimidine), 7.10 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.17 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.29 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.44 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.46–7.52 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.53–7.59 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.83–7.87 (2H, m, C<sub>6</sub>H<sub>5</sub>), 8.29 (2H, d, pyrimidine); TSPMS *m/z* 581 (M+H)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +34 (c 0.64, CH<sub>2</sub>Cl<sub>2</sub>).

**6.7.5.6. Compound 35.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[3-{(3*R*)-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate by the same procedure as employed for compound 22. Yield: (29 mg, 37% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.55–1.65 (1H, m, piperidine), 1.71–1.81 (1H, m, piperidine), 1.84–1.95 (4H, m, piperidine and tetrahydropyrimidine), 3.05 (1H, dd, piperidine), 3.08–3.18 (1H, m, piperidine), 3.25–3.38 (5H, m, piperidine and tetrahydropyrimidine), 3.42–3.54 (1H, m, piperidine), 3.54 (1H, dd, CONHCH<sub>2</sub>), 3.65–3.77 (3H, m, piperidine and CONHCH<sub>2</sub>CH), 7.13 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.27 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.32 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.47 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.48–7.53 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.54–7.60 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.85–7.90 (2H, m, C<sub>6</sub>H<sub>5</sub>); TSPMS *m/z* 529 (M+H)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +72 (c 0.55, MeOH).

#### 6.7.6. Preparation of compound 36

**6.7.6.1. Compound 36.** The title compound was prepared from compound 52 via compounds 54 and 59 by the same procedure as employed for compounds 32 from compound 51 via compounds 53 and 57. Yield: (66 mg, 20% (eight steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.64 (2H, ddd, tetrahydropyrimidine), 2.00–2.12 (1H, m, pyrrolidine), 2.21–2.31 (1H, m, pyrrolidine), 3.10–3.26 (6H, m, tetrahydropyrimidine and NHCH<sub>2</sub>), 3.51 (1H, dd, CONHCH<sub>2</sub>), 3.51–3.62 (2H, m, pyrrolidine), 3.76 (1H, dd, CONHCH<sub>2</sub>), 3.86 (1H, dd, CONHCH<sub>2</sub>CH), 4.01 (1H, ddd, pyrrolidine), 4.48 (1H, ddd, pyrrolidine), 6.74–6.78 (1H, m, C<sub>6</sub>H<sub>4</sub>), 7.04–7.10 (2H, m, C<sub>6</sub>H<sub>4</sub>), 7.27 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.50–7.56 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.56–7.62 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.86–7.91 (2H, m, C<sub>6</sub>H<sub>5</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>32</sub>N<sub>6</sub>O<sub>6</sub>S: 545.2182. Found: 545.2189; [α]<sub>D</sub><sup>25</sup> +89 (c 0.058, MeOH).

#### 6.7.7. Preparation of compound 37

**6.7.7.1. Compound 37.** The title compound was prepared from compound 54 via compounds 56 and 60 by the same procedure as employed for compound 33 from compound 53 via compounds 55 and 58. Yield: (3.1 mg, 5.3% (nine steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.56 (2H, ddd, tetrahydropyrimidine), 2.06 (1H, dddd, pyrrolidine), 2.37 (1H, dddd, pyrrolidine), 3.00–3.10 (4H, m, tetrahydropyrimidine), 3.20 (1H, ddd, pyrrolidine), 3.26 (1H, dd, NHCH<sub>2</sub>), 3.45–3.58 (3H, m, pyrrolidine and CONHCH<sub>2</sub> and NHCH<sub>2</sub>), 3.47 (3H, s, OMe), 3.78 (1H, dd, CONHCH<sub>2</sub>CH), 3.84 (1H, dd, CONHCH<sub>2</sub>), 4.08 (1H, ddd, pyrrolidine), 4.22 (1H, ddd, pyrrolidine), 6.74 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.06 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.12 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.27 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.50–7.57 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.57–7.63 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.86–7.93 (2H, m, C<sub>6</sub>H<sub>5</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>26</sub>H<sub>34</sub>N<sub>6</sub>O<sub>6</sub>S: 559.2339. Found: 559.2343.

### 6.8. Preparation of the compounds displayed in Table 5

**6.8.1. Preparation of *tert*-butyl (2*S*)-amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate, which is the common intermediate for replacement of the C-terminus**

**6.8.1.1. *tert*-Butyl (2*S*)-(benzyloxycarbonyl)amino-3-[3-{4-(pyrimidin-2-ylamino)-piperidin-1-yl}benzoylamino]propionate.** DMF (10 ml) was added to compound 26 (201 mg, 0.67 mmol) to prepare a solution, and *tert*-butyl (2*S*)-*N*-benzyloxycarbonyl-2,3-diaminopropionate (WO9938849) (212 mg, 0.74 mmol) was added to the solution. Further, 1-hydroxybenzotriazole (142 mg, 1.0 mmol), *N*-methylmorpholine (370 μl, 3.4 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (270 mg, 1.4 mmol) were added thereto, and a reaction was allowed to proceed at room temperature for 13 h. An aqueous NaHCO<sub>3</sub> solution (20 ml) was added to stop the reaction, and water (400 ml) was added thereto. The mixture was extracted twice with ethyl acetate (250 ml). The organic layers were combined, and the combined organic layers were washed with saturated brine (400 ml), were dried over anhydrous MgSO<sub>4</sub>, and were then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 20:1) to prepare the title compound (370 mg, 95%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.47 (9H, s, *t*-Bu), 1.64 (2H, m, piperidine), 2.18 (2H, m, piperidine), 2.99 (2H, dd, piperidine), 3.72 (2H, br d, piperidine), 3.82 (2H, m, CONHCH<sub>2</sub>), 4.01 (1H, m, piperidine), 4.46 (1H, m, CONHCH<sub>2</sub>CH), 5.11 (2H, s, CO<sub>2</sub>CH<sub>2</sub>Ph), 6.54 (1H, t, pyrimidine), 7.07 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.12 (1H, br d, C<sub>6</sub>H<sub>4</sub>), 7.28–7.35 (6H, m, C<sub>6</sub>H<sub>5</sub> and C<sub>6</sub>H<sub>4</sub>), 7.42 (1H, br s, C<sub>6</sub>H<sub>4</sub>), 8.28 (2H, d, pyrimidine); EIMS *m/z* 574 (M)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> –2.4 (c 1.1, CH<sub>2</sub>Cl<sub>2</sub>).

**6.8.1.2. *tert*-Butyl (2*S*)-amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate.** THF (60 ml) was added to *tert*-butyl (2*S*)-(benzyloxycarbonyl)amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate (230 mg, 0.40 mmol) to prepare a solution. To the solution was added 10% Pd/C (230 mg). The mixture was stirred in a hydrogen atmosphere at room temperature for 4 h. The insolubles were filtered and were washed with THF (200 ml). The filtrate and the washings were combined followed by concentration under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1) to prepare the title compound (110 mg, 63%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.48 (9H, s, *t*-Bu), 1.62–1.74 (2H, m, piperidine), 2.18 (2H, br d, piperidine), 2.99 (2H, br dd, piperidine), 3.48 (1H, ddd, CONHCH<sub>2</sub>), 3.61 (1H, dd, CONHCH<sub>2</sub>CH), 3.68–3.76 (2H, m, piperidine), 3.83 (1H, ddd, CONHCH<sub>2</sub>), 3.96–4.06 (1H, m, piperidine), 6.54 (1H, t, pyrimidine), 7.07 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.14 (1H, br d, C<sub>6</sub>H<sub>4</sub>), 7.29 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.43 (1H, br s, C<sub>6</sub>H<sub>4</sub>), 8.28 (2H, d, pyrimidine); EIMS *m/z* 440 (M)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +6.5 (c 1.0, CH<sub>2</sub>Cl<sub>2</sub>).

**6.8.2. Preparation of compound 38. 6.8.2.1. *tert*-Butyl (2*S*)-acetamido-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate.** CH<sub>2</sub>Cl<sub>2</sub> (10 ml) was added

to *tert*-butyl (2*S*)-amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl} benzoylamino]propionate (101 mg, 0.25 mmol) to prepare a solution. TEA (70  $\mu$ l, 0.50 mmol) and acetic anhydride (24  $\mu$ l, 0.30 mmol) were added in that order to the solution at room temperature, and a reaction was allowed to proceed for 1 h. Water (50 ml) was added thereto, and the mixture was extracted twice with CH<sub>2</sub>Cl<sub>2</sub> (100 ml). The extract was dried over anhydrous MgSO<sub>4</sub> and was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1) to prepare the title compound (94 mg, 77%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.49 (9H, s, *t*-Bu), 1.60–1.72 (2H, m, piperidine), 2.05 (3H, s, Ac), 2.19 (2H, m, piperidine), 3.00 (2H, m, piperidine), 3.68–3.75 (3H, ddd, piperidine and CONHCH<sub>2</sub>), 3.86 (1H, ddd, CONHCH<sub>2</sub>), 4.01 (1H, m, piperidine), 4.67 (1H, ddd, CONHCH<sub>2</sub>CH), 6.54 (1H, t, pyrimidine), 7.07 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.08 (1H, m, C<sub>6</sub>H<sub>4</sub>), 7.30 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.42 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 8.27 (2H, d, pyrimidine); EIMS *m/z* 482 (M)<sup>+</sup>; [ $\alpha$ ]<sub>D</sub><sup>25</sup> –6.8 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).

**6.8.2.2. Compound 38.** The title compound was prepared from *tert*-butyl (2*S*)-acetamido-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl} benzoylamino]propionate by the same procedure as employed for compound 22. Yield: (29 mg, 47% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$ : 1.64 (2H, dddd, piperidine), 1.97 (3H, s, Ac), 1.92–2.05 (4H, m, piperidine and tetrahydropyrimidine), 2.90 (2H, br dd, piperidine), 3.37 (4H, br t, tetrahydropyrimidine), 3.48 (1H, m, piperidine), 3.67 (1H, dd, CONHCH<sub>2</sub>), 3.70–3.78 (2H, m, piperidine), 3.74 (1H, dd, CONHCH<sub>2</sub>), 4.48 (1H, dd, CONHCH<sub>2</sub>CH), 7.12 (1H, m, C<sub>6</sub>H<sub>4</sub>), 7.23 (1H, br d, C<sub>6</sub>H<sub>4</sub>), 7.30 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.38 (1H, br s, C<sub>6</sub>H<sub>4</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>N<sub>6</sub>O<sub>4</sub>: 431.2407. Found: 431.2403; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +11 (*c* 0.32, MeOH).

### 6.8.3. Preparation of compound 39

**6.8.3.1. *tert*-Butyl (2*S*)-{2-(morpholin-4-yl-acetyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate.** DMF (10 ml) was added to morpholin-4-ylacetic acid (36 mg, 0.25 mmol) and *tert*-butyl (2*S*)-amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate (110 mg, 0.25 mmol) to prepare a solution. 1-Hydroxybenzotriazole (53 mg, 0.37 mmol), *N*-methylmorpholine (140  $\mu$ l, 1.3 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (97 mg, 0.50 mmol) were further added to the solution, and a reaction was allowed to proceed at room temperature for 19 h. An aqueous NaHCO<sub>3</sub> solution (5.0 ml) was added to stop the reaction, and water (100 ml) was added thereto. The mixture was extracted twice with ethyl acetate (100 ml). The combined organic layers were washed with saturated brine (100 ml), were dried over anhydrous MgSO<sub>4</sub>, and were then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1) to prepare the title compound (94 mg, 66%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.50 (9H, s, *t*-Bu), 1.65 (2H, m, piperidine), 2.18 (2H, m, piperidine), 2.55 (4H, m, piperidine and morpholine), 3.00 (2H, m, piperidine), 3.04 (2H, br d, COCH<sub>2</sub>N),

3.74 (7H, m, morpholine and CONHCH<sub>2</sub>), 3.91 (1H, ddd, CONHCH<sub>2</sub>), 4.02 (1H, m, piperidine), 4.68 (1H, ddd, CONHCH<sub>2</sub>CH), 6.55 (1H, t, pyrimidine), 7.07 (1H, m, C<sub>6</sub>H<sub>4</sub>), 7.15 (1H, br d, C<sub>6</sub>H<sub>4</sub>), 7.30 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.44 (1H, br s, C<sub>6</sub>H<sub>4</sub>), 8.28 (2H, d, pyrimidine); EIMS *m/z* 567 (M)<sup>+</sup>; [ $\alpha$ ]<sub>D</sub><sup>25</sup> –19 (*c* 1.1, CH<sub>2</sub>Cl<sub>2</sub>).

**6.8.3.2. Compound 39.** The title compound was prepared from *tert*-butyl (2*S*)-{2-(morpholin-4-yl-acetyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate by the same procedure as employed for compound 22. Yield: (42 mg, 68% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$ : 1.48 (2H, dddd, piperidine), 1.77–1.92 (4H, m, piperidine and tetrahydropyrimidine), 2.39 (4H, m, morpholine), 2.79 (2H, br dd, piperidine), 2.88 (2H, d, COCH<sub>2</sub>N), 3.24 (4H, br dd, tetrahydropyrimidine), 3.40–3.51 (3H, m, piperidine and CONHCH<sub>2</sub>), 3.55 (4H, br s, morpholine), 3.68 (2H, br dd, piperidine), 4.03 (1H, dd, CONHCH<sub>2</sub>CH), 7.01 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.13 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.25 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.32 (1H, br s, C<sub>6</sub>H<sub>4</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>37</sub>N<sub>7</sub>O<sub>5</sub>: 516.2934. Found: 516.2929; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +2.2 (*c* 0.75, MeOH).

### 6.8.4. Preparation of compound 40

**6.8.4.1. *tert*-Butyl (2*S*)-{(4-methoxybenzenesulfonyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate.** DMF (3.0 ml) was added to *tert*-butyl (2*S*)-amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate (61 mg, 0.14 mmol) to prepare a solution. *N,N*-Diisopropylethylamine (48  $\mu$ l, 0.28 mmol) and 4-methoxybenzenesulfonyl chloride (29 mg, 0.14 mmol) were added in that order to the solution at room temperature, and a reaction was allowed to proceed for 1 h. Piperazine was added to stop the reaction, and an aqueous NaHCO<sub>3</sub> solution (20 ml) and water (30 ml) were added thereto. The mixture was extracted twice with ethyl acetate (50 ml). The combined organic layers were washed twice with water (50 ml) and once with saturated brine (50 ml), were dried over anhydrous MgSO<sub>4</sub>, and were concentrated under reduced pressure to prepare the title compound (79 mg, 94%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.32 (9H, s, *t*-Bu), 1.60–1.72 (2H, m, piperidine), 2.19 (2H, br d, piperidine), 3.00 (2H, br dd, piperidine), 3.51–3.61 (1H, m, CONHCH<sub>2</sub>), 3.69–3.79 (2H, m, piperidine), 3.85 (3H, s, OMe), 3.86–3.96 (2H, m, CONHCH<sub>2</sub>CH), 3.97–4.08 (1H, m, piperidine), 6.53 (1H, t, pyrimidine), 6.95 (2H, d, C<sub>6</sub>H<sub>4</sub>OMe), 7.07 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.17 (1H, d, C<sub>6</sub>H<sub>4</sub>), 7.30 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.43 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.78 (2H, d, C<sub>6</sub>H<sub>4</sub>OMe), 8.28 (2H, d, pyrimidine); TSPMS *m/z* 611 (M+H)<sup>+</sup>; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +40 (*c* 1.6, CH<sub>2</sub>Cl<sub>2</sub>).

**6.8.4.2. Compound 40.** The title compound was prepared from *tert*-butyl (2*S*)-{(4-methoxybenzenesulfonyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate by the same procedure as employed for compound 22. Yield: (8.7 mg, 17% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$ : 1.58–1.70 (2H, m, piperidine), 1.96 (2H, dddd, tetrahydropyrimidine), 2.01 (2H, br d, piperidine), 2.92 (2H, ddd, piperidine), 3.36 (4H, br t, tetrahydropyrimidine), 3.44–3.52 (1H, m, piperidine), 3.54 (1H, dd, CONHCH<sub>2</sub>), 3.65–3.76

(2H, m, CONHCH<sub>2</sub>CH), 3.76 (2H, br d, piperidine), 3.82 (3H, s, OMe), 6.95–7.00 (2H, m, C<sub>6</sub>H<sub>4</sub>OMe), 7.13 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.24 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.30 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.43 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.76–7.80 (2H, m, C<sub>6</sub>H<sub>4</sub>OMe); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>26</sub>H<sub>34</sub>N<sub>6</sub>O<sub>6</sub>S: 559.2339. Found: 559.2343; [α]<sub>D</sub><sup>25</sup> +71 (c 0.30, MeOH).

### 6.8.5. Preparation of compound 41

**6.8.5.1. Compound 41.** 1,2-Dichloroethane (7.0 ml) was added to *tert*-butyl (2*S*)-{(4-methoxybenzenesulfonyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate (44 mg, 0.072 mmol) to prepare a solution, and a 1.0 M boron tribromide methylene chloride solution (0.40 ml) was added to the solution. A reaction was allowed to proceed at 40 °C for 3.5 h, and 1,4-dioxane (3.0 ml), water (1.0 ml), and TEA (1.0 ml) were then added thereto. The mixture was concentrated under reduced pressure. 1,4-Dioxane (20 ml) was added to the residue, followed by filtration. The filtrate was then concentrated under reduced pressure to give (2*S*)-{(4-hydroxybenzenesulfonyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid.

1,4-Dioxane (20 ml) and water (10 ml) were added to (2*S*)-{(4-hydroxybenzenesulfonyl)amino}-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid to prepare a solution, 10% Pd/C (24 mg) was added to the solution, and a reaction was allowed to proceed in a hydrogen atmosphere at room temperature for 6 h. The insolubles were filtered and were washed with a solvent (60 ml) having the same composition as the mixed solvent used in the reaction. The filtrate and the washings were combined followed by concentration under reduced pressure. The residue was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/EtOH/H<sub>2</sub>O/concd NH<sub>4</sub>OH, 8:8:1:1) and was then purified by Sephadex LH-20 (MeOH) to prepare compound 41 (11 mg, 26% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.58–1.70 (2H, m, piperidine), 1.96 (2H, dddd, tetrahydropyrimidine), 2.01 (2H, br d, piperidine), 2.87–2.98 (2H, m, piperidine), 3.36 (4H, br t, tetrahydropyrimidine), 3.43–3.53 (1H, m, piperidine), 3.53 (1H, dd, CONHCH<sub>2</sub>), 3.66–3.74 (2H, m, CONHCH<sub>2</sub>CH), 3.76 (2H, br d, piperidine), 6.81–6.85 (2H, m, C<sub>6</sub>H<sub>4</sub>OH), 7.13 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.25 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.31 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.44 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.66–7.71 (2H, m, C<sub>6</sub>H<sub>4</sub>OH); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>32</sub>N<sub>6</sub>O<sub>6</sub>S: 545.2182. Found: 545.2187; [α]<sub>D</sub><sup>25</sup> +76 (c 0.28, MeOH).

### 6.8.6. Preparation of compound 42

**6.8.6.1. Compound 42.** The title compound was prepared from *tert*-butyl (2*S*)-amino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate by the same procedure as employed for compound 40. Yield: (31 mg, 42% (three steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.64 (2H, ddd, piperidine), 1.96 (2H, dddd, tetrahydropyrimidine), 2.01 (2H, br d, piperidine), 2.23 (3H, s, Me), 2.64 (6H, s, Me), 2.91 (2H, br dd, piperidine), 3.36 (4H, br t, tetrahydropyrimidine), 3.44–3.52 (1H, m, piperidine), 3.54 (1H, dd, CONHCH<sub>2</sub>), 3.63 (1H, dd, CONHCH<sub>2</sub>), 3.69 (1H, dd, CONHCH<sub>2</sub>CH),

3.76 (2H, br d, piperidine), 6.94 (2H, s, C<sub>6</sub>H<sub>2</sub>), 7.12 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.23 (1H, ddd, C<sub>6</sub>H<sub>4</sub>), 7.30 (1H, dd, C<sub>6</sub>H<sub>4</sub>), 7.43 (1H, dd, C<sub>6</sub>H<sub>4</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>6</sub>O<sub>5</sub>S: 571.2703. Found: 571.2702; [α]<sub>D</sub><sup>25</sup> +75 (c 0.32, MeOH).

## 6.9. Preparation of the compounds displayed in Table 6

### 6.9.1. Preparation of compound 43 (method B)

**6.9.1.1. 3-Bromo-2-fluorobenzoic acid (Tetrahedron Lett. 1995, 36, 881).** THF (60 ml) was added to diisopropylamine (9.6 ml, 68 mmol) in an argon atmosphere. *n*-Butyllithium (hexane solution, 1.5 M, 38 ml, 57 mmol) was added dropwise thereto at –10 °C, and the mixture was stirred for 1 h. Separately, THF (55 ml) was added to 1-bromo-2-fluorobenzene (10 g, 57 mmol) to prepare a solution, which was then added dropwise to the lithium reagent solution at –78 °C. The mixture was stirred for 2 h and was then stirred for additional 30 min while blowing carbon dioxide thereto. The temperature of the reaction mixture was returned to room temperature, and the reaction mixture was concentrated under reduced pressure. Water (200 ml) was added to the residue to prepare a solution, and the solution was washed twice with diethyl ether (100 ml). The aqueous layer was adjusted to pH 1 by the addition of 1 N hydrochloric acid, was extracted twice with CH<sub>2</sub>Cl<sub>2</sub> (300 ml), was dried over anhydrous MgSO<sub>4</sub>, and was concentrated under reduced pressure to prepare the title compound (7.1 g, 57%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.14 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.81 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.98 (1H, ddd, C<sub>6</sub>H<sub>3</sub>); EIMS *m/z* 218, 220 (M)<sup>+</sup>.

**6.9.1.2. Ethyl 3-bromo-2-fluorobenzoate.** EtOH (30 ml) was added to 3-bromo-2-fluorobenzoic acid (3.0 g, 14 mmol) to prepare a solution. Concentrated sulfuric acid (0.30 ml) was added to the solution, and the mixture was heated under reflux for 8 h. The temperature of the reaction mixture was returned to room temperature, the reaction mixture was then slowly poured into an aqueous NaHCO<sub>3</sub> solution (500 ml), and the mixture was extracted twice with ethyl acetate (500 ml). The combined organic layers were dried over anhydrous MgSO<sub>4</sub> and were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (*n*-hexane/ethyl acetate, 4:1) to prepare the title compound (2.7 g, 79%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.40 (3H, t, Et), 4.41 (2H, q, Et), 7.10 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.73 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.87 (1H, ddd, C<sub>6</sub>H<sub>3</sub>); EIMS *m/z* 246, 248 (M)<sup>+</sup>.

**6.9.1.3. Ethyl 2-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate.** Toluene (30 ml) was added to 4-(*tert*-butyldimethylsilyloxy)piperidine (4.2 g, 20 mmol) and ethyl 3-bromo-2-fluorobenzoate (3.6 g, 15 mmol) in an argon atmosphere to prepare a solution. Tri(*tert*-butyl)phosphine (350 mg, 1.7 mmol), sodium *tert*-butoxide (2.1 g, 22 mmol), and palladium acetate (340 mg, 1.5 mmol) were added in that order to the solution, and the mixture was stirred at 80 °C for 19 h. The temperature of the reaction mixture was returned to room temperature, the insolubles were then filtered, and water (400 ml) was added thereto. The mixture was extracted twice with

ethyl acetate (200 ml), and the extract was then dried over anhydrous  $MgSO_4$  and was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel ( $CH_2Cl_2/MeOH$ , 10:1) and was then purified by column chromatography on silica gel (*n*-hexane/ethyl acetate, 1:2) to prepare the title compound (82 mg, 2.1%);  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$ : 1.39 (3H, t, Et), 1.76 (2H, dddd, piperidine), 2.00–2.09 (2H, m, piperidine), 2.87 (2H, ddd, piperidine), 3.35 (2H, m, piperidine), 3.87 (1H, dtt, piperidine), 4.38 (2H, q, Et), 7.08 (1H, dd,  $C_6H_3$ ), 7.13 (1H, ddd,  $C_6H_3$ ), 7.47 (1H, ddd,  $C_6H_3$ ); EIMS  $m/z$  267 ( $M$ )<sup>+</sup>.

**6.9.1.4. Ethyl 3-(4-aminopiperidin-1-yl)-2-fluorobenzoate.** The title compound was prepared from ethyl 2-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate by the same procedure as employed for compound 28. Yield: (85 mg, 85% (three steps));  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$ : 1.39 (3H, t, Et), 1.50–1.63 (2H, m, piperidine), 1.90–1.98 (2H, m, piperidine), 2.75 (2H, ddd, piperidine), 2.81 (1H, tt, piperidine), 3.41 (2H, br d, piperidine), 4.38 (2H, q, Et), 7.07 (1H, dd,  $C_6H_3$ ), 7.10 (1H, ddd,  $C_6H_3$ ), 7.46 (1H, ddd,  $C_6H_3$ ); EIMS  $m/z$  266 ( $M$ )<sup>+</sup>.

**6.9.1.5. Ethyl 2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate.** The title compound was prepared from ethyl 3-(4-aminopiperidin-1-yl)-2-fluorobenzoate by the same procedure as employed for compound 29. Yield: (39 mg, 38%);  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$ : 1.39 (3H, t, Et), 1.74 (2H, dddd, piperidine), 2.15–2.23 (2H, m, piperidine), 2.91 (2H, ddd, piperidine), 3.49–3.47 (2H, m, piperidine), 3.95–4.06 (1H, m, piperidine), 4.39 (2H, q, Et), 6.54 (1H, t, pyrimidine), 7.09 (1H, dd,  $C_6H_3$ ), 7.14 (1H, ddd,  $C_6H_3$ ), 7.48 (1H, ddd,  $C_6H_3$ ), 8.29 (2H, d, pyrimidine); EIMS  $m/z$  344 ( $M$ )<sup>+</sup>.

**6.9.1.6. 2-Fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid.** The title compound was prepared from ethyl 2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate by the same procedure as employed for compound 26 (method B). Yield: (18 mg, 53%);  $^1H$  NMR (400 MHz,  $DMSO-d_6$ )  $\delta$ : 1.67 (2H, m, piperidine), 1.93–2.01 (2H, m, piperidine), 2.74–2.82 (2H, m, piperidine), 3.24–3.41 (2H, m, piperidine), 3.82–3.90 (1H, m, piperidine), 6.55 (1H, t, pyrimidine), 7.16 (1H, dd,  $C_6H_3$ ), 7.26 (1H, ddd,  $C_6H_3$ ), 7.37 (1H, ddd,  $C_6H_3$ ), 8.27 (2H, d, pyrimidine); TSPMS  $m/z$  317 ( $M+H$ )<sup>+</sup>.

**6.9.1.7. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate.** The title compound was prepared from 2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid by the same procedure as employed for compound 30. Yield: (34 mg, 100%);  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$ : 1.30 (9H, s, *t*-Bu), 1.76 (2H, dddd, piperidine), 2.22 (2H, br d, piperidine), 2.92 (2H, dddd, piperidine), 3.36–3.44 (2H, m, piperidine), 3.80–3.97 (2H, t,  $CONHCH_2$ ), 3.97–4.07 (2H, m, piperidine and  $CONHCH_2CH$ ), 6.55 (1H, t, pyrimidine), 7.09–7.16 (2H, m,  $C_6H_3$ ), 7.44–7.50 (2H, m,  $C_6H_5$ ), 7.51–7.58 (2H, m,  $C_6H_3$  and  $C_6H_5$ ), 7.83–7.88 (2H, m,  $C_6H_5$ ), 8.30 (2H, d, pyrimidine); TSPMS  $m/z$  599 ( $M+H$ )<sup>+</sup>.

**6.9.1.8. Compound 43.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate by the same procedure as employed for compound 22. Yield: (16 mg, 78%);  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$ : 1.76 (2H, br ddd, piperidine), 1.96 (2H, dddd, tetrahydropyrimidine), 2.02 (2H, br d, piperidine), 2.83 (2H, br dd, piperidine), 3.33–3.50 (7H, m, piperidine and tetrahydropyrimidine), 3.66 (1H, d,  $CONHCH_2$ ), 3.68 (1H, d,  $CONHCH_2$ ), 3.74 (1H, dd,  $CONHCH_2CH$ ), 7.13–7.20 (2H, m,  $C_6H_3$ ), 7.34–7.40 (1H, m,  $C_6H_3$ ), 7.47–7.53 (2H, m,  $C_6H_5$ ), 7.53–7.59 (1H, m,  $C_6H_5$ ), 7.85–7.89 (2H, m,  $C_6H_5$ ); FAB-HRMS ( $M+H$ )<sup>+</sup> calcd  $C_{25}H_{31}N_6O_5S$ : 547.2139. Found: 547.2148; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +54 (*c* 0.27, MeOH).

## 6.9.2. Preparation of compound 44 (method B)

**6.9.2.1. Methyl 4-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate.** The title compound was prepared from methyl 3-bromo-4-fluorobenzoate and 4-hydroxypiperidine by the same procedure as employed for compound 27. Yield: (420 mg, 12%);  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$ : 1.77 (2H, m, piperidine), 2.05 (2H, m, piperidine), 2.89 (2H, ddd, piperidine), 3.39 (2H, m, piperidine), 3.87 (1H, m, piperidine), 3.90 (3H, s, Me), 7.06 (1H, dd,  $C_6H_3$ ), 7.65 (1H, ddd,  $C_6H_3$ ), 7.67 (1H, dd,  $C_6H_3$ ); FABMS  $m/z$  254 ( $M+H$ )<sup>+</sup>.

**6.9.2.2. Methyl 3-(4-aminopiperidin-1-yl)-4-fluorobenzoate.** The title compound was prepared from methyl 4-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate by the same procedure as employed for compound 28. Yield: (288 mg, 60% (three steps));  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$ : 1.57 (2H, m, piperidine), 1.95 (2H, br d, piperidine), 2.78 (2H, br t, piperidine), 2.83 (1H, m, piperidine), 3.45 (2H, br d, piperidine), 3.90 (3H, s, Me), 7.05 (1H, dd,  $C_6H_3$ ), 7.63 (1H, ddd,  $C_6H_3$ ), 7.66 (1H, dd,  $C_6H_3$ ); TSPMS  $m/z$  253 ( $M+H$ )<sup>+</sup>.

**6.9.2.3. Methyl 4-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate.** The title compound was prepared from methyl 3-(4-aminopiperidin-1-yl)-4-fluorobenzoate by the same procedure as employed for compound 29. Yield: (250 mg, 67%);  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$ : 1.74 (2H, m, piperidine), 2.21 (2H, m, piperidine), 2.93 (2H, br t, piperidine), 3.47 (2H, br d, piperidine), 3.90 (3H, s, Me), 4.01 (1H, m, piperidine), 6.54 (1H, t, pyrimidine), 7.06 (1H, dd,  $C_6H_3$ ), 7.65 (1H, ddd,  $C_6H_3$ ), 7.68 (1H, dd,  $C_6H_3$ ), 8.29 (2H, d, pyrimidine); TSPMS  $m/z$  331 ( $M+H$ )<sup>+</sup>.

**6.9.2.4. 4-Fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid.** The title compound was prepared from methyl 4-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate by the same procedure as employed for compound 26 (method B). Yield: (230 mg, 94%);  $^1H$  NMR (400 MHz,  $DMSO-d_6$ )  $\delta$ : 1.67 (2H, br dq, piperidine), 1.98 (2H, br d, piperidine), 2.81 (2H, br t, piperidine), 3.39 (2H, br d, piperidine), 3.88 (1H, m, piperidine), 6.56 (1H, t, pyrimidine), 7.24 (1H, dd,  $C_6H_3$ ), 7.56 (1H, ddd,  $C_6H_3$ ), 7.59 (1H, dd,  $C_6H_3$ ), 8.28 (2H, d, pyrimidine); TSPMS  $m/z$  317 ( $M+H$ )<sup>+</sup>.

**6.9.2.5. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[4-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate.** The title compound was prepared from 4-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid by the same procedure as employed for compound 30. Yield: (94 mg, 22%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.28 (9H, s, *t*-Bu), 1.71 (2H, m, piperidine), 2.17 (2H, m, piperidine), 2.91 (2H, br t, piperidine), 3.46 (1H, br d, piperidine), 3.59 (1H, ddd, CONHCH<sub>2</sub>), 3.89 (1H, ddd, CONHCH<sub>2</sub>), 3.97 (2H, m, CONHCH<sub>2</sub>CH and piperidine), 6.53 (1H, t, pyrimidine), 7.03 (1H, dd, C<sub>6</sub>H<sub>3</sub>), 7.32 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.49 (3H, m, 2H of C<sub>6</sub>H<sub>5</sub> and 1H of C<sub>6</sub>H<sub>3</sub>), 7.57 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.85 (2H, m, C<sub>6</sub>H<sub>5</sub>), 8.29 (2H, d, pyrimidine); FABMS *m/z* 599 (M+H)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +50 (c 1.0, CHCl<sub>3</sub>).

**6.9.2.6. Compound 44.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[4-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate by the same procedure as employed for compound 22. Yield: (52 mg, 61%); <sup>1</sup>H NMR (400 MHz, 10% concd ND<sub>4</sub>OD/CD<sub>3</sub>OD) δ: 1.64 (2H, m, piperidine), 1.89 (2H, quintet, tetrahydropyrimidine), 1.97 (2H, br d, piperidine), 2.81 (2H, br t, piperidine), 3.30 (4H, t, tetrahydropyrimidine), 3.38 (2H, br d, piperidine), 3.46 (1H, dd, CONHCH<sub>2</sub>), 3.67 (1H, dd, CONHCH<sub>2</sub>), 3.75 (1H, dd, CONHCH<sub>2</sub>CH), 7.07 (1H, dd, C<sub>6</sub>H<sub>3</sub>), 7.38 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.42 (2H, m, Ph), 7.48 (2H, m, C<sub>6</sub>H<sub>5</sub> and C<sub>6</sub>H<sub>3</sub>), 7.80 (2H, m, C<sub>6</sub>H<sub>5</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>6</sub>O<sub>5</sub>SF: 547.2139. Found: 547.2148; [α]<sub>D</sub><sup>25</sup> +63 (c 1.0, 10% concd NH<sub>4</sub>OH/MeOH).

### 6.9.3. Preparation of compound 45 (method B)

**6.9.3.1. Methyl 5-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate.** The title compound was prepared from methyl 3-bromo-5-fluorobenzoate by the same procedure as employed for compound 27. Yield: (160 mg, 4.6%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.67 (2H, dddd, piperidine), 2.01 (2H, m, piperidine), 3.02 (2H, ddd, piperidine), 3.61 (2H, ddd, piperidine), 3.90 (1H, m, piperidine), 3.90 (3H, s, CO<sub>2</sub>Me), 6.77 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.13 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.39 (1H, dd, C<sub>6</sub>H<sub>3</sub>); EIMS *m/z* 253 (M)<sup>+</sup>.

**6.9.3.2. Methyl 3-(4-aminopiperidin-1-yl)-5-fluorobenzoate.** The title compound was prepared from methyl 5-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate by the same procedure as employed for compound 28. Yield: (54 mg, 35% (three steps)); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.46 (2H, m, piperidine), 1.93 (2H, m, piperidine), 2.82–2.94 (3H, m, piperidine), 3.71 (2H, m, piperidine), 3.90 (3H, s, CO<sub>2</sub>Me), 6.76 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.12 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.52 (1H, dd, C<sub>6</sub>H<sub>3</sub>); EIMS *m/z* 252 (M)<sup>+</sup>.

**6.9.3.3. Methyl 5-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate.** The title compound was prepared from methyl 3-(4-aminopiperidin-1-yl)-5-fluorobenzoate by the same procedure as employed for compound 29. Yield: (36 mg, 51%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.63 (2H, m, piperidine), 2.18 (2H, m, piperidine), 3.01 (2H, m, piperidine), 3.72 (2H, m, piperidine),

3.91 (3H, s, CO<sub>2</sub>Me), 4.03 (1H, m, piperidine), 6.55 (1H, t, pyrimidine), 6.78 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.14 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.40 (1H, m, C<sub>6</sub>H<sub>3</sub>), 8.29 (2H, d, pyrimidine); EIMS *m/z* 330 (M)<sup>+</sup>.

**6.9.3.4. 5-Fluoro-3-{4-(pyrimidin-2-ylamino)-piperidin-1-yl}benzoic acid.** The title compound was prepared from methyl 5-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate by the same procedure as employed for compound 26 (method B). Yield: (28 mg, 91%); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 1.55 (2H, br ddd, piperidine), 1.93 (2H, br d, piperidine), 2.91 (2H, br dd, piperidine), 3.79 (2H, br d, piperidine), 3.88–4.00 (1H, m, piperidine), 6.55 (1H, t, pyrimidine), 6.96 (1H, br d, C<sub>6</sub>H<sub>3</sub>), 7.12 (1H, d, C<sub>6</sub>H<sub>3</sub>), 7.29 (1H, s, C<sub>6</sub>H<sub>3</sub>), 8.27 (2H, d, pyrimidine); EIMS *m/z* 316 (M)<sup>+</sup>.

**6.9.3.5. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[5-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate.** The title compound was prepared from 5-fluoro-3-{4-(pyrimidin-2-ylamino)-piperidin-1-yl}benzoic acid by the same procedure as employed for compound 30. Yield: (52 mg, 100%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.30 (9H, s, *t*-Bu), 1.60–1.64 (2H, m, piperidine), 2.18 (2H, br d, piperidine), 3.03 (2H, br dd, piperidine), 3.54 (1H, ddd, CONHCH<sub>2</sub>), 3.75 (2H, br d, piperidine), 3.91 (1H, ddd, CONHCH<sub>2</sub>), 3.91 (1H, m, CONHCH<sub>2</sub>CH), 3.98–4.08 (1H, m, piperidine), 6.54 (1H, t, pyrimidine), 6.72 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 6.85 (1H, br d, C<sub>6</sub>H<sub>3</sub>), 7.18 (1H, br dd, C<sub>6</sub>H<sub>3</sub>), 7.48–7.54 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.56–7.61 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.84–7.87 (2H, m, C<sub>6</sub>H<sub>5</sub>), 8.28 (2H, d, pyrimidine); EIMS *m/z* 598 (M)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +31 (c 2.2, CH<sub>2</sub>Cl<sub>2</sub>).

**6.9.3.6. Compound 45.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[5-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate by the same procedure as employed for compound 22. Yield: (27 mg, 61%); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.55–1.67 (2H, m, piperidine), 1.96 (2H, dddd, tetrahydropyrimidine), 1.96–2.03 (2H, m, piperidine), 2.95 (2H, ddd, piperidine), 3.36 (4H, br t, tetrahydropyrimidine), 3.45–3.51 (1H, m, piperidine), 3.52 (1H, dd, CONHCH<sub>2</sub>), 3.69 (1H, dd, CONHCH<sub>2</sub>), 3.77 (1H, dd, CONHCH<sub>2</sub>CH), 3.81 (2H, br d, piperidine), 6.82 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 6.91 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.24 (1H, dd, C<sub>6</sub>H<sub>3</sub>), 7.46–7.52 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.53–7.58 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.84–7.88 (2H, m, C<sub>6</sub>H<sub>5</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>6</sub>O<sub>5</sub>SF: 547.2139, found 547.2148; [α]<sub>D</sub><sup>25</sup> +64 (c 0.30, MeOH).

### 6.9.4. Preparation of compound 46 (method B)

**6.9.4.1. Methyl 6-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate.** The title compound was prepared from methyl 3-bromo-6-fluorobenzoate by the same procedure as employed for compound 27. Yield: (47 mg, 16%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.66–1.76 (2H, m, piperidine), 1.98–2.08 (2H, m, piperidine), 2.87–2.97 (2H, m, piperidine), 3.45–3.53 (2H, m, piperidine), 3.83–3.91 (1H, m, piperidine), 3.93 (3H, s, CO<sub>2</sub>Me), 7.03 (1H, br dd, C<sub>6</sub>H<sub>3</sub>), 7.08 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.45 (1H, br s, C<sub>6</sub>H<sub>3</sub>); EIMS *m/z* 253 (M)<sup>+</sup>.



**6.9.4.2. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[4-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}]benzoylamino]propionate.** The title compound was prepared from methyl 6-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate by the same procedure as employed for compound **30** from compound **27** via compounds **28** and **29**. Yield: (53 mg, 10% (six steps)); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.29 (9H, s, *t*-Bu), 1.59–1.72 (2H, m, piperidine), 2.12–2.22 (2H, m, piperidine), 2.88–2.97 (2H, m, piperidine), 3.56–3.65 (2H, m, piperidine), 3.70–3.85 (2H, m, CONHCH<sub>2</sub>), 3.90–4.00 (1H, m, piperidine), 4.13 (1H, ddd, CONHCH<sub>2</sub>CH), 6.54 (1H, t, pyrimidine), 6.98–7.10 (2H, m, C<sub>6</sub>H<sub>3</sub>), 7.43–7.49 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.50–7.55 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.57 (1H, dd, C<sub>6</sub>H<sub>3</sub>), 7.82–7.88 (2H, m, C<sub>6</sub>H<sub>5</sub>), 8.29 (2H, d, pyrimidine); EIMS *m/z* 598 (M)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +30 (c 1.1, CH<sub>2</sub>Cl<sub>2</sub>).

**6.9.4.3. Compound 46.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[4-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}]benzoylamino]propionate by the same procedure as employed for compound **22**. Yield: (8.3 mg, 14% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.65 (2H, dddd, piperidine), 1.96 (2H, dddd, tetrahydropyrimidine), 1.96–2.04 (2H, m, piperidine), 2.86 (2H, ddd, piperidine), 3.36 (4H, br t, tetrahydropyrimidine), 3.41 (1H, m, piperidine), 3.60–3.66 (2H, m, piperidine), 3.61 (1H, dd, CONHCH<sub>2</sub>), 3.70 (1H, dd, CONHCH<sub>2</sub>), 3.75 (1H, dd, CONHCH<sub>2</sub>CH), 7.06 (1H, dd, C<sub>6</sub>H<sub>3</sub>), 7.11 (1H, ddd, C<sub>6</sub>H<sub>3</sub>), 7.41 (1H, m, C<sub>6</sub>H<sub>3</sub>), 7.46–7.52 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.52–7.58 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.84–7.88 (2H, m, C<sub>6</sub>H<sub>5</sub>); FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>6</sub>O<sub>5</sub>SF: 547.2139. Found: 547.2148; [α]<sub>D</sub><sup>25</sup> +63 (c 0.20, MeOH).

### 6.9.5. Preparation of compound 47 (method C)

**6.9.5.1. Methyl 3-nitro-5-(trifluoromethyl)benzoate.** MeOH (20 ml) was added to 3-nitro-5-(trifluoromethyl)benzoic acid (5.1 g, 22 mmol) to prepare a solution, and concentrated sulfuric acid (2.0 ml) was added to the solution. The mixture was heated under reflux for 1.5 h. The temperature of the reaction mixture was returned to room temperature, and the reaction mixture was then slowly poured into NaHCO<sub>3</sub>. The insolubles were filtered, water (300 ml) was then added thereto, and the mixture was extracted twice with ethyl acetate (200 ml). The combined organic layers were dried over anhydrous MgSO<sub>4</sub> and were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (*n*-hexane/ethyl acetate, 6:1) to prepare the title compound (5.0 g, 91%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 4.04 (3H, s, CO<sub>2</sub>Me), 8.63 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 8.68 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 9.05 (1H, br s, C<sub>6</sub>H<sub>3</sub>); TSPMS *m/z* 249 (M+H)<sup>+</sup>.

**6.9.5.2. Methyl 3-amino-5-(trifluoromethyl)benzoate.** MeOH (20 ml) was added to methyl 3-nitro-5-(trifluoromethyl)benzoate (5.0 g, 20 mmol) to prepare a solution, and 10% Pd/C (3.0 g) was added to the solution. The mixture was stirred in a hydrogen atmosphere at room temperature for 23.5 h. The insolubles were filtered and were concentrated under reduced pressure to prepare the title compound (4.3 g, 100%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 3.92 (3H, s, CO<sub>2</sub>Me), 7.05 (1H,

br s, C<sub>6</sub>H<sub>3</sub>), 7.49 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.65 (1H, br s, C<sub>6</sub>H<sub>3</sub>); EIMS *m/z* 219 (M)<sup>+</sup>.

**6.9.5.3. Methyl 3-(4-hydroxypiperidin-1-yl)-5-(trifluoromethyl)benzoate.** The title compound was prepared from methyl 3-amino-5-(trifluoromethyl)benzoate by the same procedure as employed for compound **27** by method C. Yield: (4.3 g, 71% (two steps)); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.70 (2H, dddd, piperidine), 1.99–2.07 (2H, m, piperidine), 3.07 (2H, ddd, piperidine), 3.66 (2H, ddd, piperidine), 3.89–3.96 (1H, m, piperidine), 3.94 (3H, s, CO<sub>2</sub>Me), 7.28 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.69 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.74 (1H, br s, C<sub>6</sub>H<sub>3</sub>); TSPMS *m/z* 304 (M+H)<sup>+</sup>.

**6.9.5.4. *tert*-Butyl (2*S*)-benzenesulfonylamino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}-5-(trifluoromethyl)benzoylamino]propionate.** The title compound was prepared from methyl 3-(4-hydroxypiperidin-1-yl)-5-(trifluoromethyl)benzoate by the same procedure as employed for compound **30** from compound **27** via compounds **28** and **29**. Yield: (97 mg, 11% (six steps)); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.30 (9H, s, *t*-Bu), 1.49–1.74 (2H, m, piperidine), 2.20 (2H, br d, piperidine), 3.07 (2H, br t, piperidine), 3.57 (2H, ddd, CONHCH<sub>2</sub>), 3.77–3.82 (2H, m, piperidine), 3.88–3.98 (2H, m, CONHCH<sub>2</sub>CH), 4.00–4.09 (1H, m, piperidine), 6.55 (1H, t, pyrimidine), 7.22 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.38 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.46–7.52 (2H, m, C<sub>6</sub>H<sub>5</sub>), 7.54–7.60 (2H, m, C<sub>6</sub>H<sub>3</sub> and C<sub>6</sub>H<sub>5</sub>), 7.83–7.87 (2H, m, C<sub>6</sub>H<sub>5</sub>), 8.29 (2H, d, pyrimidine); TSPMS *m/z* 649 (M+H)<sup>+</sup>; [α]<sub>D</sub><sup>25</sup> +45 (c 0.63, CHCl<sub>3</sub>).

**6.9.5.5. Compound 47.** The title compound was prepared from *tert*-butyl (2*S*)-benzenesulfonylamino-3-[3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}-5-(trifluoromethyl)benzoylamino]propionate by the same procedure as employed for compound **22**. Yield: (67 mg, 73% (two steps)); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 1.69 (2H, dq, *J* = 3.6, 10.5, piperidine), 1.96 (2H, quintet, *J* = 5.8, tetrahydropyrimidine), 2.01 (2H, br d, *J* = 11.2, piperidine), 2.98 (2H, br t, *J* = 11.2, piperidine), 3.36 (4H, br t, *J* = 5.8, tetrahydropyrimidine), 3.45–3.54 (1H, m, piperidine), 3.54 (1H, dd, *J* = 8.5, 13.2, CONHCH<sub>2</sub>), 3.72 (1H, dd, *J* = 4.6, 13.2, CONHCH<sub>2</sub>), 3.80 (1H, dd, *J* = 4.6, 8.5, CONHCH<sub>2</sub>CH), 3.85 (2H, br d, *J* = 11.2, piperidine), 7.29 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.44–7.50 (3H, br s, C<sub>6</sub>H<sub>5</sub> and C<sub>6</sub>H<sub>3</sub>), 7.50–7.56 (1H, m, C<sub>6</sub>H<sub>5</sub>), 7.64 (1H, br s, C<sub>6</sub>H<sub>3</sub>), 7.83–7.87 (2H, m, C<sub>6</sub>H<sub>5</sub>); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 21.2, 32.4, 39.8, 44.4, 48.9 (d, *J*<sub>CF</sub> = 335.2 Hz), 58.7, 115.1 (q, *J*<sub>CF</sub> = 46 Hz), 115.6 (q, *J*<sub>CF</sub> = 46 Hz), 119.1, 125.6 (d, *J*<sub>CF</sub> = 1,080 Hz), 128.2, 130.1, 132.8 (q, *J*<sub>CF</sub> = 118.4 Hz), 133.7, 137.8, 141.7, 152.7, 153.8, 169.3, 175.0; FAB-HRMS (M+H)<sup>+</sup> calcd for C<sub>26</sub>H<sub>31</sub>N<sub>6</sub>O<sub>5</sub>SF<sub>3</sub>: 597.2107. Found: 597.2102; [α]<sub>D</sub><sup>25</sup> +54 (c 0.50, MeOH).

### 6.10. Integrin-binding assays

Compounds were evaluated for their inhibitory activities in α<sub>v</sub>β<sub>3</sub>- and α<sub>IIb</sub>β<sub>3</sub>-ELISA (enzyme-linked immunosorbent assay). α<sub>v</sub>β<sub>3</sub><sup>17</sup> was purified from human placenta, using RGDSPK-Sepharose CL-4B chromatography,

followed by mono Q chromatography (Pharmacia).  $\alpha_{IIb}\beta_3$ <sup>17</sup> was purified from human platelet by RGDSPK-Sepharose CL-4B.  $\alpha_v\beta_3$ - and  $\alpha_{IIb}\beta_3$ -binding assays were performed according to the modified method of Kouns et al.<sup>18</sup> EIA plates (Nunc) were coated with  $\alpha_v\beta_3$  or  $\alpha_{IIb}\beta_3$  and blocked with bovine serum albumin. In each reaction, the reaction mixture (20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl<sub>2</sub>, and 1 mM MgCl<sub>2</sub>, pH 7.4, 100  $\mu$ l) including vitronectin (Calbiochem) or fibrinogen, added to the receptor-coated plate, was incubated for 4 h at 25 °C. Thereafter the ligand binding was measured using anti-vitronectin rabbit antibody (Calbiochem) and peroxidase-conjugated anti-rabbit IgG antibody (Capell) for  $\alpha_v\beta_3$ , or peroxidase-conjugated anti-fibrinogen antibody (Capell) for  $\alpha_{IIb}\beta_3$ , and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma) as the substrate of peroxidase. The IC<sub>50</sub> values were determined from measurement of absorbance at 415 nm.

### 6.11. Adhesion of human aorta smooth muscle cells to vitronectin

The adhesion of human aorta smooth muscle cells to vitronectin was measured as described before.<sup>19</sup> Briefly EIA plates (Nunc) were coated with human vitronectin (Calbiochem) and blocked with bovine serum albumin. The cell suspension of human aorta smooth muscle cells (50,000 cells/100  $\mu$ l, Clonetics) in Dulbecco's modified Eagle's basal medium containing 0.1% bovine serum albumin was added to the vitronectin-coated plates and incubated for 1.5 h at 37 °C in the presence or absence of the test compounds. The adherent cells were stained with toluidine blue and calculated by measuring of absorbance at 405 nm after the cytolysis by SDS. The IC<sub>50</sub> values were determined graphically from two or more independent experiments.

### 6.12. Platelet aggregation assay

Platelet aggregation was determined according to the previous method.<sup>18</sup> Human platelet-rich plasma obtained from healthy volunteers was prepared and the aggregation was induced with 5  $\mu$ M ADP. The IC<sub>50</sub> values were determined from two independent experiments.

### Acknowledgments

We thank Miss Shigeko Miki and Mrs. Takako Miyara for mass spectral analysis.

### References and notes

1. Hynes, R. O. *Cell* 1992, 69, 11.

2. Byzova, T. V.; Rabbani, R.; D'Souza, S. E.; Plow, E. F. *Thromb. Haemost.* 1998, 80, 726.
3. Fujishima, K.; Murakami, S.; Yamamoto, M.; Abe, M.; Ishikawa, M.; Ouchi, S.; Ajito, K. WO0154726, 2001.
4. Kubota, D.; Ishikawa, M.; Yamamoto, M.; Murakami, S.; Hachisu, M.; Katano, K.; Ajito, K. *Bioorg. Med. Chem.*, in press.
5. Brooks, P. C. *Drug News Perspect.* 1997, 10, 456, and references cited therein.
6. Dankwardt, S. M.; Smith, D. B.; Porco, J. A., Jr.; Nguyen, C. H. *Synlett* 1997, 854.
7. Hochstein, F. A.; Els, H.; Celmer, W. D.; Shapiro, B. L.; Woodward, R. B. *J. Am. Chem. Soc.* 1960, 82, 3225.
8. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. *J. Am. Chem. Soc.* 1996, 118, 7461.
9. Guari, Y.; van Es, D. S.; Reek, J. N. H.; Kamer, P. C. J.; van Leeuwen, P. W. N. M. *Tetrahedron Lett.* 1999, 40, 3789.
10. Talma, A. G.; Jouin, P.; De Vries, J. G.; Troostwijk, C. B.; Werumeus Buning, G. H.; Waninge, J. K.; Visscher, J.; Kellogg, R. M. *J. Am. Chem. Soc.* 1985, 107, 3981.
11. Reese, C. B.; Thompson, E. A. *J. Chem. Soc., Perkin Trans. 1* 1988, 2881.
12. Ishikawa, M.; Kubota, D.; Yamamoto, M.; Kuroda, C.; Iguchi, M.; Koyanagi, A.; Murakami, S.; Ajito, K. *Bioorg. Med. Chem.*, in press.
13. Ishikawa, M.; Hiraiwa, Y.; Kubota, D.; Tsushima, M.; Watanabe, T.; Murakami, S.; Ouchi, S.; Ajito, K. *Bioorg. Med. Chem.*, in press.
14. (a) Keenan, R. M.; Miller, W. H.; Barton, L. S.; Bondinell, W. E.; Cousind, R. D.; Eppley, D. F.; Hwang, S. M.; Kwon, C.; Lago, M. A.; Nguyen, T. T.; Smith, B. R.; Uzinskas, I. N.; Yuan, C. C. K. *Bioorg. Med. Chem. Lett.* 1999, 9, 1801; (b) Pitts, W. J.; Wityak, J.; Smallheer, J. M.; Tobin, E.; Jetter, J. W.; Buynitsky, J. S.; Harlow, P. P.; Solomon, K. A.; Corjay, M. H.; Mousa, S. A.; Wexler, R. R.; Jadhav, P. K. *J. Med. Chem.* 2000, 43, 27.
15. Asanuma, H.; Kitakaze, M.; Node, K.; Sanada, S.; Ogita, H.; Takashima, S.; Asakura, M.; Minamino, T.; Tada, M.; Hori, M. *J. Am. Coll. Cardiol.* 2002, 39(Suppl 2), 300.
16. MeCN (200 ml) and EtOH (50 ml) were added to oleanomycin phosphate (25 g, 32 mmol) to prepare a solution. *p*-Toluenesulfonic acid (12 g, 65 mmol) was added to the solution, and the mixture was stirred at room temperature for 3.0 h. An aqueous Na<sub>2</sub>CO<sub>3</sub> solution was added to the reaction solution, and the mixture was extracted three times with CHCl<sub>3</sub>. The extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and was then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate) to give ethyl  $\alpha$ -L-oleandroside (3.75 g, 61%).
17. Pytela, R.; Pierschbacher, M. D.; Argraves, S.; Suzuki, S.; Rouslahti, E. *Methods Enzymol.* 1987, 144, 475.
18. Kouns, W. C.; Kirchhofer, D.; Hadvary, P.; Edenhofer, A.; Weller, T.; Pfenninger, G.; Baumgartner, H. R.; Jennings, L. K.; Steiner, B. *Blood* 1992, 80, 2539.
19. Liaw, L.; Almeida, M.; Hart, C. E.; Schwartz, S. M.; Giachelli, C. M. *Circ. Res.* 1994, 74, 214, and references cited therein.

# Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling

Yasunori Shintani<sup>1,4</sup>, Seiji Takashima<sup>1,4,\*</sup>, Yoshihiro Asano<sup>1</sup>, Hisakazu Kato<sup>1</sup>, Yulin Liao<sup>1</sup>, Satoru Yamazaki<sup>2</sup>, Osamu Tsukamoto<sup>1</sup>, Osamu Seguchi<sup>1,2</sup>, Hiroyuki Yamamoto<sup>1,2</sup>, Tomi Fukushima<sup>2</sup>, Kazuyuki Sugahara<sup>3,5</sup>, Masafumi Kitakaze<sup>2,\*</sup> and Masatsugu Hori<sup>1</sup>

<sup>1</sup>Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, <sup>2</sup>Cardiovascular Division of Medicine, National Cardiovascular Center, Suita, Japan and <sup>3</sup>Department of Biochemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe, Japan

Neuropilin-1 (NRP1) is a co-receptor for vascular endothelial growth factor (VEGF) that enhances the angiogenic signals cooperatively with VEGFR2. VEGF signaling is essential for physiological and pathological angiogenesis through its effects on vascular endothelial cells (ECs) and smooth muscle cells (SMCs), but the mechanisms coordinating this response are not well understood. Here we show that a substantial fraction of NRP1 is proteoglycan modified with either heparan sulfate or chondroitin sulfate on a single conserved Ser. The composition of the NRP1 glycosaminoglycan (GAG) chains differs between ECs and SMCs. Glycosylation increased VEGF binding in both cell types, but the differential GAG composition of NRP1 mediates opposite responsiveness to VEGF in ECs and SMCs. Finally, NRP1 expression and its GAG modification post-transcriptionally regulate VEGFR2 protein expression. These findings indicate that GAG modification of NRP1 plays a critical role in modulating VEGF signaling, and may provide new insights into physiological and pathological angiogenesis.

*The EMBO Journal* (2006) 25, 3045–3055. doi:10.1038/sj.emboj.7601188; Published online 8 June 2006

**Subject Categories:** signal transduction; proteins

**Keywords:** glycosaminoglycan; neuropilin-1; VEGF; VEGFR2

## Introduction

Neuropilin-1 (NRP1) was originally discovered as a co-receptor for semaphorin-3A (Sema3A), an axon repellent factor

\*Corresponding authors. S Takashima, Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel.: + 816 6879 3472; Fax: + 816 6879 3473; E-mail: takasima@medone.med.osaka-u.ac.jp or M Kitakaze, Cardiovascular Division of Medicine, National Cardiovascular Center, Suita, Japan. E-mail: kitakaze@zf6.so-net.ne.jp

<sup>4</sup>These authors contributed equally to this work

<sup>5</sup>Present address: Laboratory of Proteoglycan Signaling and Therapeutics, Graduate School of Life Science, Hokkaido University, Frontier Research Center for Post-genomic Science and Technology, Sapporo, Japan

Received: 13 February 2006; accepted: 16 May 2006; published online: 8 June 2006

(Kolodkin *et al.*, 1997). However, NRP1 also acts as a co-receptor for vascular endothelial growth factor (VEGF), a molecule with no sequence or structural homology to Sema3A (Soker *et al.*, 1998). VEGF (also referred as VEGF-A) is an essential factor promoting both embryonic angiogenesis and postnatal neovascularization. Additionally, VEGF plays a significant role in causing pathological angiogenesis associated with tumor growth, age-related macular degeneration, diabetic retinopathy, and other conditions (Ferrara *et al.*, 2003). Indeed, a blocking anti-VEGF antibody that disrupts VEGF signaling is a promising anticancer therapy currently in development (Hurwitz *et al.*, 2004).

VEGF has three receptors, VEGF receptor 1 and 2 (VEGFR1, VEGFR2), and neuropilin (Veikkola and Alitalo, 1999; Ferrara *et al.*, 2003). VEGFR2 is the primary receptor mediating the angiogenic activity of VEGF (Shalaby *et al.*, 1995; Ferrara *et al.*, 2003), and NRP1 functions as a co-receptor to enhance VEGFR2 signaling (Soker *et al.*, 1998). Indeed, genetic ablation of NRP1 leads to severely impaired vascular development (Kawasaki *et al.*, 1999; Takashima *et al.*, 2002; Gu *et al.*, 2003), indicating that NRP1 is essential for VEGF-mediated angiogenesis.


In addition to promoting angiogenesis, VEGF is now thought to be required for the maintenance and stabilization of mature blood vessels (Zachary, 2001; Saint-Geniez and D'Amore, 2004). Signaling through VEGFR2, VEGF induces not only endothelial cell (EC) proliferation but also cell survival (Gerber *et al.*, 1998), and the loss of VEGF signals in the choroidal endothelium is one factor promoting age-related macular degeneration (Blauwgeers *et al.*, 1999). Smooth muscle cells (SMCs), another important component of the vessel wall, also express both NRP1 (Kitsukawa *et al.*, 1995; Kawasaki *et al.*, 1999) and VEGFR2 (Grosskreutz *et al.*, 1999; Ishida *et al.*, 2001). However, SMCs in mature vessels typically do not respond to VEGF signals except in certain conditions such as atherosclerosis (Carmeliet, 2003; Jain, 2003; Khurana *et al.*, 2004). Therefore, we wished to identify the mechanism(s) responsible for different cellular responses to VEGF in ECs and SMCs.

In this study, we demonstrate that a substantial fraction of NRP1 is proteoglycan modified with either heparan sulfate (HS) or chondroitin sulfate (CS) attached to a single conserved Ser. The type of NRP1 glycosaminoglycan (GAG) chain modification differs between ECs and SMCs. Finally, we show that the type of NRP1 GAG modification critically and differentially modulates VEGFR2 signals in SMCs and ECs.

## Results

### ***A substantial fraction of NRP1 is proteoglycan modified with HS or CS***

The differential responsiveness of ECs and SMCs to VEGF could be explained by a number of factors, and we initially investigated the ability of VEGF to bind to these cells. When human coronary artery smooth muscle cells (CASMCs) were




**Figure 1** A substantial fraction of cellular NRP1 is proteoglycan, composed of either HS or CS. (A)  $^{125}\text{I}$ -labeled VEGF is crosslinked to different proteins in ECs and SMCs. Arrow indicates VEGF-binding protein specifically seen in SMCs. CASMC: coronary artery smooth muscle cell; BSMC: bronchial smooth muscle cell; HUVEC: human umbilical vein endothelial cell. (B) Western blots of exogenously expressed NRP1 in either CASMCs or HUVECs. Adenovirus encoding FLAG-tagged NRP1 was transfected 2 days before analysis at the indicated MOI. LacZ-encoding adenovirus was used as a control. (C) The high molecular weight band was not simply a covalently linked homodimer of NRP1. Only FLAG-tagged NRP1 or both FLAG-tagged and V5-tagged NRP1 were transfected in CASMCs, and the cell lysates were immunoprecipitated and detected by the indicated antibody. (D) Endogenous NRP1 was modified by GAG chain addition in both SMCs and ECs. The upper band in CASMC immunoprecipitates disappeared following treatment with both HSase and CSase. HUVEC-expressed NRP1 is also GAG modified. The band intensity was analyzed and the proportion of each glycanated form of NRP1 was determined. Data are from three separate experiments. HSase: heparitinase; CSase: chondroitinase.

incubated with  $^{125}\text{I}$ -labeled VEGF, we detected two distinct binding proteins after cell-surface crosslinking (Figure 1A). The lower band was also detected in human umbilical vein endothelial cells (HUVECs) and was identified as NRP1. However, the upper band was not found in HUVECs, and this band did not correspond to VEGFR2. In contrast, the upper band was also seen in bronchial smooth muscle cells (BSMCs) (Figure 1A), a non-vascular SMC, and, because NRP1 alone cannot transduce VEGF signals, we initially thought that this binding protein represented a new VEGF receptor. However, after transfection of CASMCs, but not HUVECs, with FLAG-tagged NRP1, we observed an identical upper molecular weight band when blotted with an anti-FLAG antibody (Figure 1B). The high molecular weight band was not simply a covalently linked homodimer of NRP1 (Figure 1C), and we reasoned NRP1 could undergo post-translational modification. Although NRP1 itself undergoes N-glycosylation, we found that the high molecular weight NRP1 was not a form of N-glycosylation or O-glycosylation by enzyme treatment and lectin blot (data not shown), but it did contain GAG chains. Indeed, treatment of NRP1 immunoprecipitates with both heparitinase and chondroitinase,

which digest HS and CS, respectively, led to the disappearance of the upper band, whereas the lower band was not affected. Next, we investigated the composition of GAG-modified endogenous NRP1 in both CASMCs and HUVECs. Heparitinase slightly decreased the modified NRP1 band in CASMCs, whereas chondroitinase digested the majority of the GAG present on NRP1, indicating that CS was the dominant GAG modification of NRP1 (Figure 1D). In contrast, NRP1 in HUVECs was also modified, but to a much lesser extent than that seen in CASMCs, and HUVEC NRP1 contained almost equivalent amounts of CS and HS (Figure 1D). By analyzing the band intensity, we determined the degree of each modification relative to untreated samples (non-modified/HS-modified/CS-modified NRP1—CASMCs: 100%/79%/174%, HUVECs: 100%/27.3%/24.6%, respectively) (Figure 1D, right panel).

GAG chains are covalently added to Ser residues of the core protein contained within a Ser-Gly consensus sequence (Esko and Zhang, 1996). We mutated the nine consensus sequences present in NRP1, and the GAG chains are attached only to Ser<sup>612</sup> (Figure 2A). As a single GAG chain cannot contain both HS and CS simultaneously, endogenous NRP1 exists as either



**Figure 2** (A) NRP1 is GAG modified on a single Ser<sup>612</sup> residue. CASCs were transfected with adenoviral vectors encoding WT or S612A mutant NRP1. NRP1 S612A is not GAG modified. (B) Multiple alignments of NRP1 from different species. Ser<sup>612</sup> is highly conserved among vertebrates. (C) NRP2, an NRP family member, is not GAG modified. (D) Design of siRNA and adenovirus constructs. Ser<sup>612</sup> exists in the bridge region between the b1b2 and MAM domains. (E) Replacement of Ser<sup>612</sup> by Ala<sup>612</sup> of NRP1 did not change binding to VEGF. Cos7 cells were transfected with either NRP1 WT' or S612A expression vector and preincubated with heparitinase (1.5 mU/ml), heparinase (1.5 mU/ml), and chondroitinase (20 mU/ml) in the culture medium at 37°C for 2 h to make NRP1 non-GAG form. After incubation with <sup>125</sup>I-labeled VEGF for 30 min at room temperature, cell lysates were immunoprecipitated by anti-NRP1 antibody, and the bound radioactivity was quantitated using a gamma counter. Data are from three independent experiments. For panel E, error bars represent s.e.


an HS proteoglycan or CS proteoglycan but not as a hybrid proteoglycan. Moreover, as shown in Figure 1D, non-modified NRP1 (130 kDa, the core protein) was always detected in both CASCs and HUVECs. Ser<sup>612</sup> is located in the bridge region between the b1b2 and MAM domains of NRP1 (Figure 2D), and multiple sequence alignments suggested that Ser<sup>612</sup> was remarkably conserved among vertebrates (Figure 2B), and the peptide sequence around Ser<sup>612</sup> was also well conserved, especially the acidic amino acids that are important for HS attachment (Esko and Zhang, 1996). NRP2, a mammalian homolog of NRP1, does not have this conserved Ser residue, and adenovirus-mediated expression of NRP2 in CASCs demonstrated that NRP2 is not GAG modified (Figure 2C).

#### GAG modification of NRP1 enhances VEGF binding

Addition of both chondroitinase and heparitinase to culture medium completely digests all GAGs attached to other core proteins on the cell surface, and this would dramatically complicate the interpretation of any experiments using this technique. Therefore, to further investigate the function of the GAG of only NRP1, we used RNAi to knock down endogenous NRP1 while expressing mutant NRP1. We designed an siRNA, named N-G, targeting the GAG attachment

site of NRP1 (Figure 2D). We further generated two NRP1-encoding adenovirus constructs: NRP1 S612A, in which Ser<sup>612</sup> was replaced by Ala<sup>612</sup> and there was a three-base mismatch with N-G siRNA; and NRP1 WT', which contains the glycan accepting residue but had a four-base mismatch with N-G siRNA (Figure 2D). In cells transfected with N-G siRNA, transfection of both adenovirus constructs led to the expression of the appropriate NRP1 molecules. We confirmed that addition of FLAG tag to NRP1 does not affect VEGF binding (data not shown) and that the mutation itself (NRP1 S612A) did not change VEGF binding to the core protein of NRP1 (Figure 2E).

We next examined the ability of VEGF to bind to experimentally replaced NRP1 in both SMCs and ECs. Transfection of both N-G siRNA and equal multiplicity of infection (MOI) adenoviral constructs successfully replaced endogenous NRP1 with either the GAG-acceptor (NRP1 WT') or mutated (NRP1 S612A) NRP1 (Figure 3A). Throughout these experiments, MOIs were used to generate NRP1 WT' or S612A expression levels comparable to endogenous NRP1. To determine whether GAG modifications affect the ability of NRP1 to bind VEGF, we measured the binding of <sup>125</sup>I-labeled VEGF to FLAG-tagged NRP1 in these cells. After incubation with <sup>125</sup>I-labeled VEGF, cell lysates were immunoprecipitated with an



**Figure 3** GAG modifications differentially affect NRP1 function in SMCs and ECs. (A) Experimental replacement of NRP1 in SMCs and ECs. After transfection with both N-G siRNA and adenoviral constructs, endogenous NRP1 was successfully replaced with either the glycanated form (NRP1 WT') or non-glycanated form (NRP1 S612A) of NRP1. Tubulin was used as a loading control. (B) Addition of GAG to NRP1 enhances binding to VEGF in both types of cells. Two days after NRP1 replacement, cell lysates were immunoprecipitated with anti-FLAG antibody after incubation with <sup>125</sup>I-labeled VEGF (25 ng/ml) for 40 min at room temperature, and bound radioactivity was quantitated using a gamma counter. Heparitinase and chondroitinase treatment with these immunoprecipitates could not entirely eliminate the enhancement of VEGF binding (Figure 3B), different from the results of Figure 2E in which we showed that VEGF equally binds NRP1 WT' and S612A pretreated with heparitinase and chondroitinase before the exposure to VEGF. These results suggest that GAG modifications of NRP1 in SMCs and ECs enhance VEGF binding mainly to NRP1 core protein and not to only GAG chain of NRP1. (C) VEGF (50 ng/ml) induced greater cell migration in SMCs expressing non-modified NRP1 S612A than those expressing NRP1 WT'. Migrated cells were quantified by counting cells in three random high-power fields (HPF, × 200). Similar results were obtained from additional two independent experiments. (D) VEGF (50 ng/ml) increased cell viability in ECs expressing NRP1 WT' to a greater extent than in ECs expressing NRP1 S612A. Data are from three independent experiments. For panels B-D, error bars represent s.e. \*P<0.05, versus adeno-NRP1 WT' in panel B.

anti-FLAG antibody, and bound radioactivity was counted. NRP1 WT' bound VEGF with 3.87- and 2.27-fold higher than NRP1 S612A in SMCs and ECs, respectively (Figure 3B). We found that heparitinase and chondroitinase treatment with these immunoprecipitates could not entirely eliminate the enhancement of VEGF binding (Figure 3B), different from the results of Figure 2E in which we showed that VEGF equally binds NRP1 WT' and S612A pretreated with heparitinase and chondroitinase before the exposure to VEGF. These results suggest that GAG modifications of NRP1 in SMCs and ECs enhance VEGF binding mainly to NRP1 core protein and not to only GAG chain of NRP1.

#### **NRP1 GAG modifications lead to differential VEGF responsiveness in SMCs and ECs**

We next investigated whether GAG modifications of NRP1 in both SMCs and ECs affected cellular responsiveness to VEGF. VEGF increases the motility of vascular SMCs (Grosskreutz *et al*, 1999; Ishida *et al*, 2001), and induces proliferation, migration, and cell survival in ECs (Ferrara *et al*, 2003). These

actions are primarily mediated through the VEGFR2 signaling pathway likely in conjunction with NRP1.

Notably, VEGF induced the migration of SMCs expressing NRP1 S612A (non-modified) stronger than those expressing NRP1 WT' (GAG modified) (Figure 3C). In contrast, VEGF increased the viability of ECs expressing NRP1 WT' to a greater extent than those expressing NRP1 S612A (Figure 3D). The observed increased viability seen in ECs expressing NRP1 WT' in response to VEGF is consistent with the increased VEGF binding shown in Figure 3B. However, the decreased motility seen in SMCs expressing NRP1 WT' was unexpected. To further explore this discrepancy, we examined the influence of different GAG chains on the expression of VEGFR2 and the formation of the VEGF-VEGFR2-NRP1 ternary complex, both important determinants of VEGF signaling (Soker *et al*, 2002).

We first analyzed VEGFR2 protein expression in cells expressing either NRP1 WT' or S612A. In SMCs expressing S612A mutant, VEGFR2 expression was two-fold higher than in cells expressing NRP1 WT' (Figure 4A (left) and B), but

expression of either NRP1 WT' or S612A did not affect VEGFR2 expression in ECs (Figure 4A (right) and B). The increased VEGFR2 protein expression in SMCs was not accompanied by changes in mRNA levels (Figure 4C), indicating that post-transcriptional mechanisms regulate VEGFR2 expression.

Both the extent of GAG modification and the predominant GAG chain added (i.e. HS or CS) differ between ECs and SMCs. Therefore, we examined whether the type of GAG modification affected ternary complex formation. We used enzymatic digestions and <sup>125</sup>I-labeled VEGF binding to assess the contribution of CS- and HS-modified NRP1 to VEGF binding, and found that all forms of NRP1 bound VEGF equally well (Figure 4D). We next examined the ability of GAG-modified NRP1 to associate with VEGFR2 in the presence of VEGF by co-immunoprecipitation. After pretreatment with heparitinase and/or chondroitinase, V5-tagged VEGFR2 was precipitated from SMC lysates in the presence of VEGF. As shown in Figure 4E, CS-modified NRP1 minimally associated with VEGFR2 compared to non-modified or HS-modified NRP1.

Thus, in SMCs, GAG-modified NRP1 post-transcriptionally downregulates VEGFR2 expression, and CS-modified NRP1 may act as a decoy receptor, rather than a co-receptor. It is likely that a combination of these factors explains the differences in VEGF activity seen in SMCs expressing NRP1 WT' or S612A (Figure 3C).

Based on the results of receptor complex formation in the presence of VEGF in Figure 4E, we hypothesized that NRP1 might affect VEGFR2 internalization/degradation after ligand binding, because degradation of the receptor tyrosine kinase is an important regulator of signaling intensity (Duval *et al*, 2003; Rubin *et al*, 2005). Before exposure to VEGF, VEGFR2 expression was not different between ECs expressing NRP1 WT' and S612A (Figure 4A). However, the rate of VEGFR2 degradation was decreased in NRP1 WT' ECs compared to NRP1 S612A ECs. Phosphorylated VEGFR2 was also much higher in ECs expressing NRP1 WT' than those expressing NRP1 S612A at any time points after VEGF (Figure 4F). These results suggested that the GAG modification of NRP1 enhances VEGF signaling in ECs by delaying the degradation of VEGFR2 in the presence of VEGF, and not just by the enhancement of VEGF binding.

#### **NRP1 post-transcriptionally modulates VEGFR2 expression**

NRP1 knockout mice exhibit severely impaired vascular development and die around E13.5 (Kitsukawa *et al*, 1995; Kawasaki *et al*, 1999). VEGF has several splicing isoforms (its major forms in mice are VEGF<sub>120</sub>, <sub>164</sub>, <sub>188</sub>) and NRP1 does not bind VEGF<sub>120</sub>. In contrast, VEGFR2 can bind all of VEGF isoforms. Although NRP1 is a common receptor for both VEGF and Sema3A, impaired VEGF signaling is responsible for the observed vascular defects in these mice (Gu *et al*, 2003). However, the vascular defect in NRP1<sup>-/-</sup> mice is more severe than that seen in VEGF<sup>120/120</sup> mice, in which only VEGF<sub>120</sub> is expressed (Carmeliet *et al*, 1999; Stalmans *et al*, 2003). Thus, NRP1 appears to play a more prominent role in VEGF signaling than simply functioning as a co-receptor for some VEGF isoforms. Based on the results that CS-dominant GAG of NRP1 negatively affects VEGFR2 expression levels in SMCs, we hypothesized that NRP1 basically

stabilizes VEGFR2 leading to increased expression. Thus, VEGFR2 expression should be lower in NRP1<sup>-/-</sup> mice, leading to a more pronounced vascular phenotype.

To test this hypothesis in cells, we knocked down NRP1 in ECs using siRNA. Before the addition of VEGF, VEGFR2 expression was substantially decreased in cells transfected with NRP1 siRNAs (Figure 5A). Two siRNAs targeting NRP1 were used to exclude the possibility of an off-target effect of RNAi. VEGFR2 mRNA levels were unaffected by NRP1 knockdown, however (Figure 5B). Additionally, VEGFR1, another VEGF receptor, was not affected by either NRP1 siRNA, suggesting that NRP1 specifically regulates VEGFR2 expression (Figure 5A). As VEGFR2 protein level was not associated with transcription level, we conducted pulse-chase experiments in HUVECs treated with NRP1 siRNA to determine the rate of VEGFR2 degradation in the absence of VEGF. Notably, we found that the rate of VEGFR2 degradation was not changed by NRP1 knockdown (Figure 5C), which was different from the results in the presence of VEGF (Figure 4F).

We next examined whether the ability of NRP1 to promote VEGFR2 expression was specific for ECs, and we generated Flp293/VEGFR2 cells stably expressing VEGFR2. These cells express much less NRP1 than either ECs or SMCs. When these cells were transfected with NRP1, NRP1 was GAG modified similar to ECs (Figure 5D), and VEGFR2 expression was substantially upregulated (Figure 5D). VEGFR2 transcription was not altered by NRP1 expression (data not shown). Finally, when transfected cells were examined by confocal microscopy, NRP1-expressing cells had substantially higher cell-surface VEGFR2 levels compared to non-transfected adjacent cells (Figure 5E).

## **Discussion**


### **NRP1 GAG modifications differentially regulate VEGF responsiveness in SMCs and ECs**

In this study, we showed that a substantial fraction of NRP1 is proteoglycan modified with either HS or CS on a single conserved Ser residue. Additionally, both the degree and length of GAG modification and the predominant side chain added differ between ECs and SMCs. In both ECs and SMCs, GAG modifications enhanced VEGF binding, but GAG addition to NRP1 in ECs enhanced VEGF-VEGFR2 signaling. In contrast, GAG-modified NRP1 negatively affected VEGF activity in SMCs. Interestingly, in SMCs, GAG modification of NRP1 post-transcriptionally downregulates VEGFR2 expression, and CS-modified NRP1, the major form of NRP1 in SMCs (about 50% of total NRP1), may act as a decoy receptor, rather than a co-receptor.

The mechanism by which the addition of GAGs to NRP1 enhanced VEGF signals in ECs remains unclear. We speculate that the addition of HS chains to NRP1 promotes multimerization. Exogenous heparin and HS bind NRP1 via its b1b2 domain and increase VEGF binding to NRP1 and VEGFR2 (Gitay-Goren *et al*, 1992; Mamluk *et al*, 2002). Additionally, heparin can induce NRP1 multimerization in the presence or absence of ligands (Fuh *et al*, 2000; Mamluk *et al*, 2002). Binding between the NRP1 b1b2 domain and HS requires only eight highly sulfated monosaccharide units (Mamluk *et al*, 2002). Generally, in a single HS chain, sulfated sugar residues occur in multiple clusters (containing 6–10 sugars)

separated by regions of low sulfation (Gallagher, 2001). We estimated the length of a single HS chain of NRP1 as about 50 kDa in ECs including at least 200 monosaccharide units, and this modification is sufficient to bind multiple NRP1 molecules. Therefore, we speculate that a single NRP1 HS chain could bind multiple NRP1 molecules and promote NRP1 clustering. Such an NRP1 cluster could recruit substantial amounts of VEGFR2, and, in the presence of VEGF,

increase the binding frequency without affecting the dissociation constant. When the receptor complex with VEGF and VEGFR2 is formed, VEGFR2 might stabilize and escape internalization/degradation, and as a result it enhances VEGF signal (as in Figure 4F). In contrast to HS, the role of CS in VEGF signaling has not been well investigated. We found that only chondroitin sulfate-E (CS-E, a subclass of CS chains) enhances VEGF binding to NRP1 in ECs like heparin







allosteric effects in SMCs. Further structural studies examining the interaction of GAG-modified NRP1 with VEGFR2 will clarify this issue.

NRP1 is also a receptor for Semaphorin 3A (Kolodkin *et al*, 1997). It was recently found that GAG regulates the function of Semaphorin 5A, a member of a different class of the semaphorin family. Semaphorin 5A is able to exert both attractive and repulsive effects, depending on association with HS and CS, respectively (Kantor *et al*, 2004). This intriguing report raises the possibility that GAG chains of NRP1 might also regulate Semaphorin 3A binding and function. Further study is needed to clarify the role of GAG modifications on NRP1/Semaphorin 3A signaling. Furthermore, it was recently reported that FGF2 binds NRP1 (West *et al*, 2005). It might be interesting to search the role of GAG modifications of NRP1 on FGF2 signaling.

#### **What is the physiological relevance of GAG-mediated differences in VEGF responsiveness in vascular cells?**

The addition of GAG chains to NRP1 led to opposite effects on VEGFR2 signaling in ECs and SMCs. SMCs migrate in response to VEGF, and this migration is mediated mainly through VEGFR2. However, cell density or passage number affects SMC response to VEGF (Ishida *et al*, 2001). We identified a specific lot of SMCs expressing comparable levels of VEGFR2 as ECs. In these cells, the pattern of NRP1 GAG modification was similar to that of ECs seen in this study (Y Shintani and S Takashima, unpublished observations). Additionally, GAG chain modifications changed with time in culture or by incubating in ischemic conditions (preliminary data). Thus, different ill-defined culture conditions can cause changes in GAG addition to NRP1, and this can affect VEGF signaling in both SMCs and ECs.

Based on the present results, it appears that differential GAG chain addition to NRP1 can mediate opposite responses to VEGF in ECs and SMCs in mature blood vessels. In contrast, during active angiogenesis, SMCs need to migrate and enclose ECs to form complete vessels. Under these circumstances, both ECs and SMCs might express NRP1 with short GAG chains and respond similarly to VEGF for efficient vessel formation. Indeed, VEGF has also been recently implicated in the normal development of SMC-surrounded coronary arteries and pericyte coverage in the retinal vasculature (Benjamin *et al*, 1998; Carmeliet *et al*, 1999). Further investigation will be needed to clarify the *in vivo* composition of GAG chains of NRP1.

#### **NRP1 post-transcriptionally regulates the expression of VEGFR2**

We demonstrated that knockdown of NRP1 by RNAi post-transcriptionally reduced VEGFR2 expression in ECs, suggesting that NRP1 positively regulates the expression of VEGFR2. In contrast, GAG addition to NRP1 in SMCs eliminated this effect. As the transcription of VEGFR2 was not affected by NRP1 expression or GAG modification, we conclude that VEGFR2 expression is post-transcriptionally regulated by NRP1.

Cell-surface proteins undergo a complex process including co-translational folding, post-translational modifications, and transport through various cellular compartments including the ER and Golgi apparatus. Recent reports suggest that stable cell-surface receptor expression in the absence of ligand

sometimes requires a specific adaptor protein or co-receptor (McLatchie *et al*, 1998; Loconto *et al*, 2003; Saito *et al*, 2004). Most identified receptors are complex proteins with seven transmembrane domains, but a type I membrane receptor such as VEGFR2 could also require such an adaptor or co-receptor, for example, NRP1. NRP1 and VEGFR2 might interact in the absence of VEGF and the addition of CS to NRP1 interferes with the trafficking and/or stability of VEGFR2.

Our findings suggested that NRP1 is a key modulator of VEGF signaling. Further studies and technical advances are needed to precisely characterize the importance of particular GAG modifications on VEGF signaling *in vitro* and *in vivo*. However, the role of NRP1 and its post-translational modifications may provide new insights into the growth of vascular networks in physiological and pathological conditions.

## **Materials and methods**

### **Materials**

We utilized the following commercially available antibodies: anti-NRP1 antibody (C-19, Santa Cruz Inc.), anti-human VEGFR2 for Western blot (A-3, Santa Cruz Inc.), for immunofluorescent study (ab9530, Abcam), for immunoprecipitation (C-1158, Santa Cruz Inc.), anti-alpha-tubulin (clone B-5-1-2, Sigma), anti-VEGFR1 (C-17, Santa Cruz Inc.), anti-FLAG M2 (Sigma), anti-V5 (Invitrogen), PY20-HRP-conjugated antibody (BD Biosciences). Heparitinase, heparinase, and chondroitinase were purchased from Seikagaku Corp.

### **Preparation, radioiodination of VEGF, and chemical crosslinking**

Recombinant human VEGF<sub>165</sub> was prepared in Hi5 cells using the baculovirus system (Invitrogen) and purified with two-step chromatography to over 95% purity as determined by silver stain. Na<sup>125</sup>I was purchased from Amersham Biosciences, and <sup>125</sup>I-labeled VEGF was prepared using IODO-BEADS (Pierce). <sup>125</sup>I-labeled VEGF crosslinking study was performed as described previously (Soker *et al*, 1998). Briefly, cells were grown to 90–95% confluence in a 60 mm collagen 1-coated dish and labeled with <sup>125</sup>I-labeled VEGF (25 ng/ml) using DSS (Pierce) according to the manufacturer's instructions. Cells were lysed with 1% Nonidet P-40 containing buffer (1% Nonidet P-40, 0.15 M NaCl, 20 mM Tris pH 7.2, including protease inhibitor cocktail (Nacalai)) and then subjected to SDS-PAGE using 5–10% gradient gel (Bio-Rad). Bound <sup>125</sup>I-labeled VEGF was detected by autoradiography using the BAS system (Fuji). For competitive binding analysis (Figure 4D), CASCAMC was transfected with FLAG-tagged NRP1 at MOI 10 2 days before the experiment. After crosslinking, cells lysates were immunoprecipitated with anti-FLAG M2 antibody, and immunoprecipitates were then subjected to heparitinase (1.25 mU/ml) or chondroitinase (250 mU/ml) treatment. Cold VEGF was added 5 min before <sup>125</sup>I-labeled VEGF for assessing binding affinity.

### **Expression vector and adenovirus constructs**

Human NRP1 cDNA was obtained as described previously (Soker *et al*, 1998). In this experiment, all construction was performed using the Gateway system (Invitrogen) according to the manufacturer's instructions. With PCR primer designed to include or delete stop codon of NRP1, the amplified fragment was inserted into pENTR/D-TOPO (Invitrogen), named pENTR/NRP1 or pENTR/NRP1-cV5, respectively. To generate N-terminal FLAG-tagged NRP1 (NRP1 FLAG), FLAG epitope (DYKDDDDK) was inserted just after the signal sequence of NRP1 (between Lys<sup>26</sup> and Cys<sup>27</sup>) by PCR-based mutagenesis using pENTR/NRP1 as a template. Both NRP1 WT' and S612A were also generated by PCR-based mutagenesis (primer design is shown in Figure 2C). All the NRP1 constructs were recombined to mammalian expression vector, pEF-DEST51 (Invitrogen) and pAd/CMV/V5-DEST (Invitrogen). Adenovirus constructs were generated using ViraPower Adenoviral Expression System (Invitrogen) essentially as described by the manufacturer. Recombined vectors along with the supplied pAd/CMV/V5-DEST/lacZ were transfected into host HEK293A cells (Invitrogen). NRP2

and VEGFR2 cDNAs were cloned into pENTR/D-TOPO from HUVEC cDNA. Both adenoviruses and expression vectors of non-tagged and V5-tagged NRP2 and VEGFR2 were generated as those of NRP1.

#### Cell culture

HUVECs, human CASMCs, human BSMCs, and human aortic smooth muscle cells (AoSMCs) were obtained from Clonetics. They were cultured in endothelial and smooth muscle cell medium (Clonetics) and used up to passage 5.

#### Treatment with heparitinase and chondroitinase, and analysis of the proportion of each glycanated NRP1

Cells were lysed with lysis buffer (0.15 M NaCl, 1 mM EDTA, 20 mM Tris pH 7.2, including protease inhibitor cocktail (Nacalai)). The aliquots of lysates were incubated with anti-NRP1 antibody (C-19), followed by addition of Protein G Sepharose (Amersham Bioscience) for 1–2 h at 4°C. Bound NRP1 was then subjected to heparitinase and/or chondroitinase treatment in enzyme-contained buffer (1% Nonidet P-40, 0.15 M NaCl,  $5 \times 10^{-5}$  M  $\text{Ca}^{2+}$ , 20 mM Tris pH 7.2, including heparitinase (1.25 mU/ml) and/or chondroitinase (25 mU/ml)) at 37°C for 1 h. Enzyme-treated immunoprecipitates were subjected to SDS-PAGE and Western blotting. By analyzing the band intensity using ImageJ software (version 1.34s), the proportion of each glycanated form of NRP1 was determined.

#### RNAi and adenovirus transfection, experimental replacement of NRP1 with/without GAG

HUVECs at 50–70% confluency were transfected with the indicated siRNA duplexes using Optifect (Invitrogen) according to the manufacturer's instructions. AoSMCs (for Western blot, RT-PCR, VEGF binding and migration assay) or CASMCs (for  $^{125}\text{I}$ -labeled VEGF crosslinking and co-immunoprecipitation) at 80–90% confluency were transfected with Lipofectamine 2000 (Invitrogen). siRNA was transfected at 50 nM in a 60 or 100 mm dish 4–6 h after plating. After another 4 h, adeno- LacZ, NRP1 WT', or S612A was infected at an MOI of 2 (for ECs) or 4–6 (for SMCs). NRP1 siRNAs were synthesized by Dharmacon Inc., and siRNAs sequences were as follows: N-G: sense 5'-cugccacaguggaacaggu-dTdT, N-1: sense 5'-gagaguccugaauuguucc-dTdT. N-1 was the same sequence that had been previously reported (Bachelder *et al*, 2003). siRNA for non-silencing control used in this study was targeted for GL2: sense 5'-cguacgcggaauucgca-dTdT (Elbashir *et al*, 2001). We chose this oligonucleotide as control because VEGFR2 and NRP1 expression level was not affected as compared with non-transfected cells, different from other several non-silencing control siRNAs that are commercially available.

#### $^{125}\text{I}$ -labeled VEGF binding to NRP1

Two days after transfection with siRNA (N-G) and adeno-NRP1 WT' or S612A, both SMCs and ECs were incubated with  $^{125}\text{I}$ -labeled VEGF (25 ng/ml) for 40 min at room temperature. The cells were washed twice with PBS and lysed with lysis buffer (0.15 M NaCl, 1 mM EDTA, 20 mM Tris pH 7.2, including protease inhibitor cocktail (Nacalai)). Cell lysates were immunoprecipitated with anti-FLAG M2 agarose (Sigma) for 1 h at 4°C. After washing with buffer twice, the immunoprecipitates were subjected to gamma counter (Beckman).

#### Cell migration assay

Effects of VEGF on SMCs migration were studied using 24-well Transwell® microplate (Corning Inc.). Pore (8.0  $\mu\text{m}$ ) polystyrene filters were treated with 10  $\mu\text{g}/\text{ml}$  fibronectin (Sigma). Two days after the transfection with RNAi (N-G) and respective adenovirus (NRP1 WT' or S612A), AoSMCs were trypsinized and then loaded into the inner chamber at  $1 \times 10^4$  cells/well. After incubation with or without VEGF (1, 10, 50 ng/ml) or 10% FBS at 37°C for 6 h in a  $\text{CO}_2$  incubator, the upper side of the filters containing non-migrated cells was wiped and rinsed. The filters were fixed and stained with Diff-Quik®. Migrating cells were quantified by counting cells in each well at three random high-power fields ( $\times 200$ ). All groups were studied in triplicate.

#### Cell viability

Cell viability was assessed with a CellTiter 96 Aqueous One Solution Cell Proliferation Assay System (Promega). HUVECs were plated in a 96-well culture plate at a density of  $5 \times 10^4$  cells/well in 0.5% FBS in EBM2 medium (Clontech). Six hours after plating,

siRNA was transfected using Optifect at 100 nM; consequently, adenovirus addition was performed at MOI 2. Serum starvation with or without VEGF (50 ng/ml) was performed 24 h after transfection and MTS reagent was added to each well 24 h later, and optical absorbance at 490 nm was measured with a microplate reader.

#### Quantitative RT-PCR

Total RNA was extracted using RNA-Bee-RNA Isolation Reagent (Tel-Test Inc.). Then, 1  $\mu\text{g}$  of total RNA was reverse-transcribed using Omniscript RT (Qiagen) according to the manufacturer's protocol. Quantitative RT-PCR was performed with TaqMan technology using the ABI Prism 7000 detection system (Applied Biosystems) according to the manufacturer's instructions. RT-PCR conditions were 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were normalized to 18S ribosome or GAPDH level. Each sample was analyzed in duplicate and the experiments were replicated twice for the full set of genes. For 18S ribosome, GAPDH, VEGFR1, and VEGFR2, primers and probes were obtained using TaqMan Assays-on-Demand gene expression products (Applied Biosystems). For NRP1, primer sequences were as follows: sense 5'-CAAGGTGTTTCATGAGGAAGTTCAA, antisense 5'-CCGCAGCTCAGGTGATCATAGT, probe FAM-5'-TGACAGCAAACC CAAGCGAAGTCTT-TAMRA.

#### Co-immunoprecipitation assay

HEK293T cells in a 60 mm dish were transfected with 5  $\mu\text{g}$  of pEF-DEST51/VEGFR2 V5 using Lipofectamine 2000. Two days after transfection, we treated the cells with both 10 mU heparitinase and 200 mU chondroitinase in serum-free medium to eliminate extracellular GAG for 2 h at 37°C. Then, cells were lysed in lysis buffer (1% Nonidet P-40, 0.15 M NaCl, 20 mM Tris pH 7.2, including protease inhibitor cocktail (Nacalai)). We also prepared four sets of endogenous CASMCs (100 mm plate, each), which were treated with heparitinase alone, chondroitinase alone, both heparitinase and chondroitinase, or none in serum-free medium for 2 h at 37°C. We then mixed with the aliquot of enzyme-treated VEGFR2 V5 cell lysates and the lysate of each enzyme-treated CASMCs and incubated with anti-V5 agarose (Sigma) in the presence or absence of VEGF (50 ng/ml) for 3 h at 4°C. After extensive washing, immunoprecipitated samples were subjected to SDS-PAGE and Western blotting.

#### Pulse-chase experiments

HUVECs were transfected with control or N-G siRNA. Two days after transfection, cells were labeled for 20 min at 37°C with 20  $\mu\text{Ci}$  [ $^{35}\text{S}$ ]methionine per milliliter in methionine-free Dulbecco's modified Eagle's medium (DMEM; Invitrogen). The cells were then washed and chased in DMEM containing 10% FBS for the indicated time periods. At each time point of the chase, cell lysates were immunoprecipitated with anti-VEGFR2 antibody (C-1158) for 2 h at 4°C. The immunoprecipitates were subjected to SDS-PAGE using 5% polyacrylamide gel. Labeled VEGFR2 was visualized by autoradiography and quantified using the BAS system (Fuji).

#### Generation of stable cell line

We generated 293 cells which stably expressed VEGFR2 using the Flp-In system (Invitrogen) according to manufacturer's instructions. After VEGFR2 cDNA in the pENTR/D-TOPO was recombined to pEF5/FRT/V5-DEST (Invitrogen), we transfected this construct to Flp293 cells (Invitrogen) with Lipofectamine 2000 (Invitrogen) and established the 293/VEGFR2 cells by selection with 250  $\mu\text{g}/\text{ml}$  hygromycin (Invitrogen).

#### Immunofluorescent staining

Flp293/VEGFR2 cells were transfected with pDEST51-NRP1 FLAG using Optifect (Invitrogen) on a poly-D-lysine-coated chamber-slide (Nunc). Two days later, cells were fixed with 2% paraformaldehyde in PBS for 15 min at room temperature, washed twice in 0.1 M glycine/PBS, and blocked with 10% FBS/PBS for 30 min at room temperature. The cells were probed with anti-VEGFR2 antibody (1:400 dilution in 10% FBS/PBS) for 1 h, then washed and incubated with AlexaFluor 488-conjugated goat antibody against mouse IgG (1:1000 dilution in 10% FBS/PBS; Molecular Probes) for 1 h. The cells were washed thoroughly and then probed with anti-FLAG M2 antibodies conjugated with Cy3 (1:1000 dilution in 10% FBS/PBS; Sigma) for 1 h. We mounted the preparations using

PermaFluor Mountant Medium (Thermo) and took images with Radiance 2100 (Bio-Rad).

#### Data analysis

Statistical significance was assessed with ANOVA using the Fisher's *post hoc* test. A value of  $P < 0.05$  was considered to be statistically significant.

#### Supplementary data

Supplementary data are available at *The EMBO Journal* Online.

## References

- Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, Mercurio AM (2003) Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. *Cancer Res* **63**: 5230–5233
- Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. *Development* **125**: 1591–1598
- Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijlstra A, van Hinsbergh VW, Schlingemann RO (1999) Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. *Am J Pathol* **155**: 421–428
- Carmeliet P (2003) Angiogenesis in health and disease. *Nat Med* **9**: 653–660
- Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard JC, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D'Amore PA, Shima DT (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. *Nat Med* **5**: 495–502
- Duval M, Bedard-Goulet S, Delisle C, Gratton JP (2003) Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells. *J Biol Chem* **278**: 20091–20097
- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**: 494–498
- Esko JD, Zhang L (1996) Influence of core protein sequence on glycosaminoglycan assembly. *Curr Opin Struct Biol* **6**: 663–670
- Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. *Nat Med* **9**: 669–676
- Fuh G, Garcia KC, de Vos AM (2000) The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. *J Biol Chem* **275**: 26690–26695
- Gallagher JT (2001) Heparan sulfate: growth control with a restricted sequence menu. *J Clin Invest* **108**: 357–361
- Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. *J Biol Chem* **273**: 13313–13316
- Gitay-Goren H, Soker S, Vlodevsky I, Neufeld G (1992) The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. *J Biol Chem* **267**: 6093–6098
- Grosskreutz CL, Anand-Apte B, Duplaa C, Quinn TP, Terman BI, Zetter B, D'Amore PA (1999) Vascular endothelial growth factor-induced migration of vascular smooth muscle cells *in vitro*. *Microvasc Res* **58**: 128–136
- Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsche B, Richards LJ, Kolodkin AL, Ginty DD (2003) Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. *Dev Cell* **5**: 45–57
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* **350**: 2335–2342
- Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M, Wijelath ES (2001) Expression of vascular endothelial growth factor receptors in smooth muscle cells. *J Cell Physiol* **188**: 359–368
- Jain RK (2003) Molecular regulation of vessel maturation. *Nat Med* **9**: 685–693
- Kantor DB, Chivatakarn O, Peer KL, Oster SF, Inatani M, Hansen MJ, Flanagan JG, Yamaguchi Y, Sretavan DW, Giger RJ, Kolodkin AL (2004) Semaphorin 5A is a bifunctional axon guidance cue regulated by heparan and chondroitin sulfate proteoglycans. *Neuron* **44**: 961–975
- Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H (1999) A requirement for neuropilin-1 in embryonic vessel formation. *Development* **126**: 4895–4902
- Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, Ferrara N, Martin JF, Zachary I, Simons M (2004) Angiogenesis-dependent and independent phases of intimal hyperplasia. *Circulation* **110**: 2436–2443
- Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H (1995) Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. *Development* **121**: 4309–4318
- Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD (1997) Neuropilin is a semaphorin III receptor. *Cell* **90**: 753–762
- Loconto J, Papes F, Chang E, Stowers L, Jones EP, Takada T, Kumanovics A, Fischer Lindahl K, Dulac C (2003) Functional expression of murine V2R pheromone receptors involves selective association with the M10 and M1 families of MHC class Ib molecules. *Cell* **112**: 607–618
- Mamluk R, Gechman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M (2002) Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. *J Biol Chem* **277**: 24818–24825
- McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* **393**: 333–339
- Rubin C, Gur G, Yarden Y (2005) Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitination. *Cell Res* **15**: 66–71
- Saint-Geniez M, D'Amore PA (2004) Development and pathology of the hyaloid, choroidal and retinal vasculature. *Int J Dev Biol* **48**: 1045–1058
- Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H (2004) RTP family members induce functional expression of mammalian odorant receptors. *Cell* **119**: 679–691
- Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* **376**: 62–66
- Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. *J Cell Biochem* **85**: 357–368
- Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell* **92**: 735–745
- Stalmans I, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der Ohe M, Swillen A, Maes C, Gewillig M, Molin DG, Hellings P, Boetel T, Haardt M, Compnolle V, Dewerchin M, Plaisance S, Vlietinck R, Emanuel B, Gittenberger-de Groot AC,

## Acknowledgements

We thank Drs M Takahashi, N Taniguchi, S Yamada, and H Kitagawa for thoughtful discussion, and A Ogal, Y Nagamachi, H Okuda, and M Nakamura for technical assistance. We thank Drs T Toyofuku and R Iwamoto for reading the manuscript. This study is supported by Grant-in-aid for Scientific Research (nos.16390225, 17390229) from the Ministry of Education, Science and Culture, Japan, a Grant from Japan Cardiovascular Research Foundation, and the Human Frontier Science Program.